The QualityStocks Daily Stock List
- American Church Mortgage Company (ACMC)
- Chemesis International, Inc. (CADMF)
- Emerald Health Therapeutics, Inc. (EMHTF)
- International Land Alliance, Inc. (ILAL)
- Kraig Biocraft Laboratories, Inc. (KBLB)
- ProtoKinetix, Incorporated (PKTX)
- Rise Gold Corp. (RYES)
- StrikeForce Technologies, Inc. (SFOR)
- Rezolute, Inc. (RZLT)
- Thin Film Electronics ASA (TFECF)
- Geospatial Corp. (GSPH)
- Escalon Medical Corp. (ESMC)
- Vilacto Bio, Inc. (VIBI)
- RedHawk Holdings Corp. (IDNG)
American Church Mortgage Company (ACMC)
Penny Stock Tweets, Street Insider, Market Screener, Value Never Sleeps, The Stock Market Watch, Altcoin Mercury, Wallet Investor, Investors Hangout, Dividend Investor, Stockhouse, Last10k, Simply Wall St, Stockopedia, and InvestorsHub reported earlier on American Church Mortgage Company (ACMC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
American Church Mortgage Company makes mortgage loans to churches in the USA and this is the Company’s specialty. It works with hundreds of churches annually and offers an array of financing options tailored to a church's needs. ACMC’s affiliate is American Investors Group, Inc. American Church Mortgage Company (ACMC) is a Real Estate Investment Trust, or REIT. Established in 1994, the Company has its corporate headquarters in Minnetonka, Minnesota. It lists on the OTC Markets.
ACMC and American Investors Group are Direct Lenders - not a mortgage broker or other intermediary. They work to be the lowest cost source of construction and long-term financing to churches in the U.S. The Company is not associated with commercial banks, credit unions or other short-term lenders who provide only adjustable-rate loans with short term maturities and balloon payments. ACMC provides flexible loan terms and conditions. It avoids the restrictive covenants that characterize other lenders.
ACMC has options for permanent long-term loans, construction loans, refinances, property purchases, and also renovations. The Company offers long-term, fixed rate financing with no balloon payments, no prepayment penalties, and no personal guarantees. Moreover, it will work with a client’s mortgage broker.
ACMC has financed hundreds of purchases, construction, refinancing, and renovation projects ranging from $300,000 to greater than $5 million. The Company can work together with church architects, construction professionals, as well as capital campaign advisors to help a church realize all its goals.
For greater than three decades ACMC’s affiliate, American Investors Group, has been a foremost church bond underwriter. It can fund loans in all 50 States. The firm is a registered securities broker-dealer established in 1987 to provide investments and investment banking opportunities to individuals and institutional clients.
American Investors Group is a member of the Financial Industry Regulatory Authority (FINRA); Securities Investors Protection Corporation (SIPC); and the National Association of Church and Institutional Financing Organization (NACIFO). It is registered with the Securities and Exchange Commission (SEC).
American Church Mortgage Company (ACMC), closed Wednesday's trading session at $1.12, even for the day, on 13,962 volume with 38 trades. The average volume for the last 3 months is 11,507 and the stock's 52-week low/high is $0.319999992/$5.25.
Chemesis International, Inc. (CADMF)
Green Stock Report, Trading View, GlobeNewswire, Technical420, Insider Financial, CannabisMarketCap, CannabisFN, OTC Markets, InvestorsHub, Tip Ranks, Market Screener, Stockhouse, Stockwatch, MarketBeat, Small Caps Daily, The Trading Letter, Financial Buzz, Midas Letter, Business Insider, Investing News, Canadian Insider, Dividend Investor, and Insider Tracking reported earlier on Chemesis International, Inc. (CADMF), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.
Chemesis International, Inc. is a vertically integrated global leader in the cannabis industry. At present, it operates within California, Puerto Rico, and Colombia, The Company is developing a strong presence in important markets. This is from cultivation, to manufacturing, distribution and retail. OTCQB-listed, Chemesis International is based in Vancouver, British Columbia.
The Company has facilities in Puerto Rico and California, allowing for the cost effective production and distribution of its products. In addition, Chemesis leverages exclusive brands and partnerships. It also uses the highest quality extraction methods to provide consumers with first-class cannabis products. The Company is in the process of constructing a GMP certified facility in Colombia. Its Puerto Rico operations are licensed to operate 100,000 ft2 of cultivation, and 35,000 ft2 of manufacturing floor space.
Chemesis International, with its international reach and exclusive partnerships, is working to establish and grow new markets worldwide. It has current operations underway in Puerto Rico with Natural Ventures, in Colombia with La Finca, and in California with California Sap and Desert Zen.
Chemesis has its state-of-the-art grow facility in Puerto Rico that highlights a 2,000-plus grow light capacity and a 30,000-plus lb overall grow capacity. Also, La Finca brings more than 1,000 acres of land for cultivation in Colombia. Chemesis has greater than 2,000 relationships with farming families that comprise its land package.
Concerning Distribution, Chemesis’ Desert Zen presently has a major presence in Southern California. The Company has a fleet of fully compliant vehicles that are servicing the State.
Pertaining to Retail Sales, Chemesis is now retailing exclusive products in Puerto Rico and engaging retail storefronts in the California market. It is also working to open exclusively branded shops in manifold markets. It distributes and transports California Sap, Jay and Silent Bob’s Private Stash, and 3rd party brands to over 600 dispensaries in California and Puerto Rico.
Regarding Manufacturing, the Company can provide it’s clients all types of extractions, formulations and products, specializing in BHO Extraction, Alchohol Extraction, and CO2 Extraction. Currently, Chemesis has the capacity to process in excess of 2,000 lbs of raw material daily.
Recently, Chemesis International announced a Partnership with U.S. based Happy Tea, a brand of CBD infused sachets and shots. The Partnership allows Happy Tea to expand its product offering and achieve cost savings through taking advantage of Chemesis International’s extraction, finished goods manufacturing and retail distribution. Happy Tea offers three products including powdered drink mixes and flavoured oil shots that consist of a blend of all-natural ingredients, antioxidants, and are infused with 10mg of CBD.
Chemesis International will assist Happy Tea in expanding its present three SKU’s to an expanded product line of nine SKU’s. Chemesis will manufacture Happy Tea products in its U.S. based facilities and will increase production as demand increases. With this Partnership, Chemesis received a USD $4,000,000 minimum purchase order to manufacture products. As demand grows and Happy Tea expands its product catalogue, more contracts will be added to ensure sufficient supply.
Chemesis International, Inc. (CADMF), closed Wednesday's trading session at $1.6843, up 0.255952%, on 82,309 volume with 121 trades. The average volume for the last 3 months is 83,582 and the stock's 52-week low/high is $0.949999988/$2.03159999.
Emerald Health Therapeutics, Inc. (EMHTF)
New Cannabis Ventures, Stockwatch, Daily Marijuana Observer, NIC Investors, Proactive Investors, Micro Cap Daily, Investing Haven, Small Cap Power, Stock of the Week, Green Leaf Pot Stocks, Pot Stock News, Micro Small Cap, Midas Letter, Technical420, Trading View, Wallet Investor, Insider Financial, Stockhouse, and Barchart reported beforehand on Emerald Health Therapeutics, Inc. (EMHTF), and today we report on the Company, here at the QualityStocks Daily Newsletter.
Emerald Health Therapeutics, Inc., together with its subsidiaries, produces and sells medical cannabis in Canada. It is a Health Canada Licensed Producer (LP) of medical cannabis with decades of experience in pharmaceutical innovation. The Company previously went by the name T-Bird Pharma, Inc. It changed its corporate name to Emerald Health Therapeutics, Inc. in June 2015. Emerald is a vertically integrated, seed-to-sale company. OTCQX-listed, Emerald Health Therapeutics is based in Victoria, British Columbia.
The Company is part of the Emerald Health group. The Emerald Health group is broadly centered on developing pharmaceutical, botanical, and nutraceutical products that may provide wellness and medical benefits through interacting with the human body’s endocannabinoid system.
Emerald Health Therapeutics’ concentration is on enhancing health via cannabis science. The Company produces and sells dried cannabis and cannabis oil for medical and recreational purposes. It has combined core competencies from decades of experience in pharmaceutical innovation with large-scale agriculture expertise focused on developing value-added cannabis-based products with potential wellness and medical benefits.
Emerald is leveraging industry-leading life sciences, cannabis, and greenhouse growing expertise to realize highly competitive, low cost, value-added cannabis products. It entered into a strategic alliance with Factors R&D Technology, Inc., a division of Factors Group of Nutritional Companies, Inc., Canada’s largest nutritional supplement marketer and manufacturer. The exclusive arrangement provides access to an industrial-scale production facility, capable of processing up to 1M kg of biomass per year and softgel production capacity of up to 600M capsules per year.
Emerald has secured cannabis supply agreements with the Provinces of British Columbia, Alberta, Saskatchewan, Ontario, Québec, Newfoundland and Labrador, and the Yukon Territory. It is advancing prospective supply agreements with all remaining Provinces and Territories to develop a significant presence in the recreational market.
Emerald purchased 500 acres of harvested hemp chaff in 2018 ,and up to 1,000 acres in 2019 to 2022 from Emerald Health Hemp, Inc. CBD extract from hemp biomass will be used in its medical and adult-use products.
This month, Emerald Health Therapeutics announced that its 50 percent-owned joint venture (JV) for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, attained its full production run-rate of 75,000 kilograms of dried cannabis at its 1.1 million square foot Delta 3 greenhouse in Delta, British Columbia.
Furthermore, Emerald announced this month that it received its cultivation license from Health Canada for the 12-acre outdoor grow area at its new organic cannabis operation in Metro Vancouver, British Columbia. The expectation is that the outdoor grow area will capable of producing roughly 10,000 kg of cannabis annually with numerous crops during a full growing season. With this license effective as of July 12, 2019, the Company states that it is positioned to deliver one harvest and a portion of the expected full production volume in 2019.
Emerald Health Therapeutics, Inc. (EMHTF), closed Wednesday's trading session at $6.38, off by 11.7566%, on 12,441 volume with 22 trades. The average volume for the last 3 months is 1,852 and the stock's 52-week low/high is $6.15000009/$14.00.
International Land Alliance, Inc. (ILAL)
Interactive Brokers, OTC Markets, StockNews, Stockwatch, GlobeNewswire, Simply Wall St, and Investors Hangout reported previously on International Land Alliance, Inc. (ILAL), and today we report on the Company, here at the QualityStocks Daily Newsletter.
International Land Alliance, Inc. is an international land investment and development organization based in San Diego, California. Its focus is on acquiring attractive raw land mainly in Northern Baja California, often within driving distance from Southern California. The Company’s primary aim is to sell desirable properties, at competitive prices, with favorable financing options for individual purchases and/or bulk purchases suitable for all types of investors and buyers. International Land Alliance lists on the OTC Markets Group’s OTCQB.
In essence, International Land Alliance offers the option of financing with a guaranteed acceptance on any purchase for every customer. Through removing the middleman, loans are approved directly by the Company. This provides easy and affordable financing terms. Also, there are no prepayment penalties, credit or background checks, and very competitively low interest rates.
International Land Alliance’s inventory includes properties that are residential, commercial, recreational, waterfront, ranch, hotel, and marina. The Company, via its wholly-owned subsidiary, International Land Alliance, S.A. de C.V, a Mexican corporation, is the owner of 123 residential lots and commercial lots comprising a total of 20-acres, called Valle Divino, situated in Ensenada, Baja California. Additionally, it is the owner of 1,344 residential lots and commercial lots comprising 497-acres, named Oasis Park Resort, located in San Felipe, Baja California.
The Oasis Park Resort and Valle Divino Resort projects will undergo development as a second home resort or retirement destination in a planned community setting. The Company’s Villas Del Enologo at Rancho Tecate is a 2.6 acre parcel within the prestigious Rancho Tecate. It is a planned 24 -2B/2B Vineyard Villas with private wine cellar.
This past March, International Land Alliance closed on the purchase of 80 acres, the Emerald Grove Estates, and an 8,000 square foot event facility, the Chateau at Emerald Grove, in the wine country in Southern California for $1.1 million. It entered into a 3-year lease with future plans of development.
On the whole, International Land Alliance owns a total of four different real estate development properties consisting of close to 600 acres of land. These properties are all in southern California or Northern Baja California, Mexico. The Company states that upon full development, the properties could potentially yield 1,510-plus residential lots and 11 commercial lots, all of which it intends to sell.
International Land Alliance has commenced final site preparation on its Valle Divino development. Valle Divino is part of a 1,250-acre master planned residential community overlooking the globally-renowned Bajamar Ocean Front Hotel and Golf Course and the Pacific Ocean.
At the beginning of July, International Land Alliance announced it started the permitting process to sell up to an additional 900 residential lots roughly 1/10th acre each with starting prices at $14,900 next to its Oasis Park Resort in San Felipe, Baja California. This new phase is across the Coastal Highway 5 from the Company’s present development on the Sea of Cortez. The expectation is that Pre-Sales will begin in Q4 of this year.
International Land Alliance, Inc. (ILAL), closed Wednesday's trading session at $1.41, off by 2.7586%, on 5,515 volume with 21 trades. The average volume for the last 3 months is 8,679 and the stock's 52-week low/high is $1.12/$3.40000009.
Kraig Biocraft Laboratories, Inc. (KBLB)
Investor Village, StockPulse, Insider Financial, Simply Wall St, Super Stock Screener, TipRanks, Discovery Stocks, Emerging Growth, Wallet Investor, Infront Analytics, InvestorsHub, Stockhouse, and Trading View reported beforehand on Kraig Biocraft Laboratories, Inc. (KBLB), and we also highlight the Company, here at the QualityStocks Daily Newsletter.
Kraig Biocraft Laboratories, Inc. is the top developer of genetically engineered spider silk based fibers. The OTCQB-listed has attained a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry. Its genetic engineering research has succeeded in developing what many consider to be the holy grail of material science - a practical and cost-effective technology for producing recombinant spider silk based fibers on an industrial scale. Kraig Biocraft Laboratories is based in Ann Arbor, Michigan.
At its inception, Kraig Biocraft Laboratories obtained proprietary genetic engineering technology to unlock the mystery of producing spider silk. In early 2006, it obtained certain exclusive rights from the University of Wyoming to use the spider silk gene sequences in the Company’s field of use. Spider Silk is among the strongest fibers produced in nature. Some spider species can produce up to seven different types of silk depending upon the spider’s particular need at that time. Spider silk holds the potential of a lifesaving ballistic resistant material - lighter, thinner, flexible and tougher than steel material.
Currently, Kraig Biocraft Laboratories is ramping up production of its Monster Silk™ and Dragon Silk™ for commercialization. The Company is also continuing to develop new and recombinant spider silk fibers.
This past April, Polartec and Kraig Biocraft Laboratories announced plans to bring to market the first fabrics made from spider silk. First developed for specialized military applications, these first-of-their-type materials made from recombinant spider silk will ultimately service the worldwide market for high performance textiles and apparel. Polartec is the premium provider of innovative and sustainable textile solutions.
Recently, Kraig Biocraft Laboratories announced the creation of the next generation of recombinant spider silk using its new design, gene editing, and incorporation approaches. The Company designed this approach to customize mechanical properties for specific commercial markets. It has demonstrated the ability to more rapidly, accurately, and efficiently generate new transgenics.
The Company states that this is the material science breakthrough that it has been pushing for since creating the Dragon Silk line. The new transgenic was specifically engineered for high strength and considerably higher protein expression levels. This achievement marks a major milestone in Kraig Biocraft Laboratories’ corporate mission to produce and commercialize eco-friendly materials that surpass the performance and strength of native spider silk.
Earlier this month, Kraig Biocraft Laboratories announced that it was awarded an increased investment license for expansion of its recombinant spider silk production at Prodigy Textiles, the Company’s Vietnamese subsidiary. With this new license, the Vietnamese government increased Kraig Biocraft’s potential investment cap to as high as USD $50 million. This substantially increased investment limit will now enable the Company to prepare for the second phase expansion, planned for a 123 acre site near Prodigy Textiles’ existing facility, and is part of Kraig’s systematic and structured plan to expand capacity.
Kraig Biocraft Laboratories, Inc. (KBLB), closed Wednesday's trading session at $1.455, up 5.4348%, on 147,954 volume with 173 trades. The average volume for the last 3 months is 8,679 and the stock's 52-week low/high is $0.174999997/$3.21000003.
ProtoKinetix, Incorporated (PKTX)
OTC PR Group, Allstocks, Stockwatch, Investor Village, ResearchPool, Trading View, 4-Traders, and Wallet Investor reported previously on ProtoKinetix, Incorporated (PKTX), and today we report on the Company, here at the QualityStocks Daily Newsletter.
ProtoKinetix, Incorporated provides medical researchers with a platform for enhancing cell survival and health, in vitro and in vivo. A molecular biotechnology company, it has developed and patented a family of hyper stable, potent glycopeptides (AAGP®), which enhance engraftment and protection of transplanted cells, organs, tissues and organs used in regenerative medicine. OTCQB-listed, ProtoKinetix has its corporate office in Marietta, Ohio.
At the heart of its technology is its patented anti-aging glycopeptide AAGP™. This small molecule (580 Daltons) displays abilities in resolving challenges facing medical researchers in areas including regenerative medicine and as a therapy for diseases relating to tissue inflammation and oxidation stress. Because of its stability, small size and molecular makeup, it maintains its function in vivo without triggering the body's immune system. It can also function without toxic side effects typical in treatments involving larger and less stable compounds. AAGP™ is manufactured at facilities in North America, Europe, and Asia for shipment internationally.
ProtoKinetix is building value through the independent research of laboratories, university and private, into applications for its AAGP™ molecule. Concerning health solutions, there are two principal categories that AAGP™ applications would be divided into. One is regenerative Medicine issues. This includes harvesting, processing, storage and transplanting cells, tissues and organs. The other is treatments for chronic inflammatory conditions and diseases caused by stress factors. This includes UV radiation, oxidation, as well as cryopreservation and hydrogen cyanide.
Because of the results realized over the last four years of testing, the University of Alberta has begun Phase 1 human clinical trials. Additional studies will be expanded to include whole organ transplantation and all therapies that are undergoing development globally to date; diabetes, retinal degeneration, cardiac repair and numerous other degenerative conditions. Furthermore, ProtoKinetix is studying the potential impact on several cancer therapies.
This month, ProtoKinetix announced that it reached the mid-point of 3rd stage of testing in retinal cell replacement therapy at the University of British Columbia. The Company states that functionality testing on experimental models three months post-transplant show encouraging results. It anticipates results from six-month post-transplant to be available within the next 4-5 weeks (from July 9, 2019).
This study includes two experimental models over a longer period of time to test whether the AAGP® treated cells continue to develop and mature into retinal cells to potentially restore vision in humans. The Gregory-Evans Retinal Therapeutic Lab at the University of British Columbia is conducting the study.
ProtoKinetix, Incorporated (PKTX), closed Wednesday's trading session at $0.32, up 6.6667%, on 39,894 volume with 12 trades. The average volume for the last 3 months is 9,726 and the stock's 52-week low/high is $0.05/$0.319999992.
Rise Gold Corp. (RYES)
Streetwise Reports, 24hgold, Junior Mining Network, The Prospector News, Metals News, Geology for Investors, Market Screener, Infront Analytics, Newsfile, Pinnacle Digest, Infront Analytics, Wallet Investor, InvestorsHub, Stockwatch, Simply Wall St, Dividend Investor, MarketBeat, Investor Ideas, Stockopedia, and Stockhouse reported previously on Rise Gold Corp. (RYES), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
An exploration-stage mining company, Rise Gold Corp.’s chief asset is the historic past-producing Idaho-Maryland Gold Mine positioned in Nevada County, California. The gold-quartz mines of the Grass Valley-Nevada City District in Nevada County have been the most productive in California. The Idaho-Maryland Gold Mine was a major past producer, yielding 2,414,000 oz of gold at an average mill head grade of 17 gpt gold from 1866-1955. The Company previously went by the name Rise Resources, Inc. It changed its name to Rise Gold Corp. in April of 2017. OTCQB-listed and formed in 2007, Rise Gold has its corporate headquarters in Vancouver, British Columbia.
There exists manifold exploration targets on this property that is fully owned by Rise Gold. This includes surface and mineral rights. The Company has 100 percent ownership on what is private land (2,800 acres of subsurface land; 175 acres of industrial land). The property has all the mineral rights of the historic Idaho-Maryland Mine and there are no royalties on future gold production.
The Idaho-Maryland Gold Mine features advanced targets with known mineralization. The Mine was one of the most prolific past gold producers in the United States. It was forced by the U.S. government to shut down in 1942 at peak production for WWII. It was the second largest lode gold mine in the entire United States before shutdown. A major expansion to double production was completed in 1942 prior to shutdown.
This past March, Rise Gold announced that it intersected 90 gpt gold over 4.3 m at the Idaho-Maryland Mine. Of note is individual assays of up to 458.0 gpt gold over 0.81 m (13.4 oz per ton over 2.7 ft). It is interpreted to be a down-dip extension of the Idaho #1 Vein. More drilling targeting the Idaho #1 Vein is in progress.
In June, Rise Gold announced the successful completion of the initial surface exploration drilling program, the estimation of a significant Initial Exploration Target based on recent exploration drilling, and its strategy to advance the Idaho-Maryland (I-M) Gold Project towards the re-opening of the mine. Rise completed 19 drill holes, totalling 20,584 meters, over the past 20 months in its initial surface exploration drilling program at the I-M Gold Project.
Drilling confirmed the presence of significant extensions of earlier mined veins and structures. Many high-grade gold intercepts were encountered near the existing mine workings and to depths of more than 1 km below historic mining areas.
Earlier this month, Rise Gold announced that at the request of the Investment Industry Regulatory Organization of Canada, the Company is pleased to provide a range of gold grades for the Initial Exploration Target earlier disclosed and clarifications to its news release dated June 28, 2019 for the I-M Gold Project. The Initial Exploration Target is between 2,280,000 - 3,410,000 tons (2,068,000 - 3,094,000 tonnes) of mineralized material with grades ranging from 0.19 - 0.30 oz per ton gold (6.5 - 10.3 grams per tonne) and containing 432,000 - 1,019,000 oz gold.
Rise Gold clarifies that the Initial Exploration Target is only "conceptual in nature." It is not an "estimate" of mineral resources. Rise Gold retracts the use of the word "estimate" in conjunction with the calculation of the Initial Exploration Target.
Rise Gold Corp. (RYES), closed Wednesday's trading session at $2.19, up 0.004566%, on 28,486 volume with 69 trades. The average volume for the last 3 months is 28,281 and the stock's 52-week low/high is $2.03999996/$5.06264019.
StrikeForce Technologies, Inc. (SFOR)
The OTC Reporter, Capital Cube, Stockhouse, Silicon Investors, Insider Financial, Simply Wall St, Investing, Stockopedia, Tip Ranks, OTC Markets, MarketWatch, Penny Stock Tweets, Barchart, YCharts, GuruFocus, Morningstar, Investors Hangout, InvestorsHub, Street Insider, and Nasdaq.com reported earlier on StrikeForce Technologies, Inc. (SFOR), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
StrikeForce Technologies, Inc. provides strong two-factor, “Out-of-Band” authentication, and keystroke encryption along with mobile solutions. The Company helps to prevent Cyber theft and data security breaches for consumers, corporations, and government agencies. OTCQB-listed, StrikeForce Technologies is headquartered in Edison, New Jersey. BlockSafe Technologies is a subsidiary company of StrikeForce Technologies.
StrikeForce’s three chief products are ProtectID® (authentication), MobileTrust® (mobile device application), and GuardedID® (keystroke encryption). ProtectID® has an array of potential authentications methods. These methods include Out-of-Band Phone; Out-of-Band Push; Hard Tokens; Mobile Tokens; as well as Desktop Tokens.
GuardedID® stops malicious keylogging programs. It does so through encrypting keystroke data and routing it directly to one’s internet browser or desktop via a secure pathway that is invisible to keyloggers. MobileTrust® eliminates the threat from keylogging hackers. It does so through preventing them from detecting ones’ keystrokes.
StrikeForce provides the above-mentioned “Out-of-Band Authentication” and “Endpoint Protection” utilizing keystroke encryption, for signing on securely to one’s bank, broker, retail stores, and more. Also, the Company provides mobile device security on one’s Apple or Android devices.
The Company’s BlockSafe Technologies subsidiary centers on providing security solutions to protect blockchain and cryptocurrencies. BlockSafe Technologies will offer three innovatively redesigned security solutions. The first is Blockchain Defender™. The Company states that this will be the industry’s most completely dedicated Blockchain firewall. The other two solutions are Desktop Defender™ and Mobile Defender™. These two products will protect digital wallets and cryptocurrencies on MS Windows, Apple, iOS, and also Android platforms.
Recently, StrikeForce Technologies and Caroni Solutions, LLC announced the official Ecuadorian and South American product launch of StrikeForce Technologies ProtectID®.
Andrés Merino, South America spokesperson for Caroni Solutions, said, "We're excited to partner with industry leader StrikeForce Technologies to deliver the industry's most versatile, flexible and cost-effective multi-factor Out-of-Band authentication platform. ProtectID® is an affordable, flexible, and redundant authentication technology that Ecuador's banks, corporations, universities, and government agencies need to protect their networks and customers."
StrikeForce Technologies, Inc. (SFOR), closed Wednesday's trading session at $0.38, up 15.1515%, on 48,350 volume with 13 trades. The average volume for the last 3 months is 12,200 and the stock's 52-week low/high is $0.090000003/$0.495999991.
Rezolute, Inc. (RZLT)
Spotlight Growth, Emerging Growth, MarketWatch, Dividend Investor, Market Screener, OTC Markets, Simply Wall St, GuruFocus, Street Insider, Investing Online, The Street, Stockopedia, Morningstar, InvestorsHub, 4-Traders, Barchart, last10k, Stockhouse, YCharts and Wallet Investor reported earlier on FieldPoint Petroleum Corp. (RZLT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Rezolute, Inc. is a clinical stage biopharmaceutical company headquartered in Louisville, Colorado. It specializes in the development of innovative drug therapies for metabolic and orphan diseases. The Company formerly went by the name AntriaBio, Inc. It changed its corporate name to Rezolute, Inc. in December of 2017. Rezolute’s shares trade on the OTC Markets Group’s OTCQB.
Rezolute is advancing a divers pipeline. This pipeline includes RZ358 (Phase 2). This is an antibody for the ultra-orphan indication of Congenital HyperInsulinism (CHI), with an abbreviated path-to-market strategy. In addition, the pipeline includes AB101 (Phase 1). This is a once-weekly injectable basal insulin with the potential to transform the treatment landscape in diabetes management through reducing the therapeutic burden for patients and improving compliance.
The Company’s pipeline also includes a Plasma Kallikrein Inhibitor (PKI) portfolio with two lead compounds. One is RZ402 targeting Diabetic Macular Edema (DME). The other is RZ602 targeting Hereditary Angioedema (HAE), an orphan indication.
Rezolute and XOMA Corporation have executed a license agreement. The agreement provides Rezolute with the exclusive international rights to develop and commercialize RZ358 (formerly XOMA 358) for Congenital Hyperinsulinism (CHI), an ultra-orphan indication. XOMA is a pioneer in the discovery, development, as well as licensing of therapeutic antibodies.
RZ358 is a first-in-class fully human monoclonal antibody. It counteracts the effects of elevated insulin via allosteric modulation of the insulin receptor. This makes it well-suited as a therapy for severe, persistent hypoglycemia caused by hyperinsulinemic conditions such as CHI.
Recently, Rezolute announced that it entered into a $25 million preferred stock purchase agreement with two pharmaceutical companies that have elected to make a strategic investment in Rezolute. The investors include Handok, Inc., and Genexine, Inc., two premier publicly traded South Korean-based pharmaceutical companies. These two have a collective market capitalization of greater than $1.7 billion. With this agreement, each preferred share is priced at $5.00 and automatically converts into shares of Rezolute’s common stock at an implied per share price of $0.22.
Rezolute’s intention is to use the proceeds from this offering to advance its clinical programs. This includes initiating a Phase 2b clinical study for RZ358 in the U.S. and Europe; completing the required toxicology studies for RZ402 to enable the filing of an IND and initiation of clinical studies; and completing an ongoing Phase 1 study for AB101.
FieldPoint Petroleum Corp. (RZLT), closed Wednesday's trading session at $0.131, up 274.2857%, on 1,049,000 volume with 371 trades. The average volume for the last 3 months is 5,034 and the stock's 52-week low/high is $0.035/$0.230000004.
Thin Film Electronics ASA (TFECF)
Speculating Stocks, Dividend Investor, Wallet Investor, Penny Stock Millionaire, Penny Stock Tweets, Stockhouse, TradingView, OTC Markets, InvestorsHub, The Street and 4-Traders reported earlier on Thin Film Electronics ASA (TFECF), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.
Thin Film Electronics ASA provides near field communication (NFC) mobile marketing and smart-packaging solutions by printed electronics technology. It provides end-to-end mobile marketing solutions that feature hardware, label/packaging integration services, and a robust cloud-based software platform.
OTCQX-listed, Thin Film Electronics is based in Oslo, Norway. Additionally, the Company has offices in Silicon Valley, Sweden, San Francisco, London, and Shanghai.
Thin Film’s vision is to make everyday items ‘just smart enough’, thus, effectively extending the traditional boundaries of the IoT to create the Internet of Everything. The Company has 270 patents and patents-pending.
Thin Film’s products include NFC Solutions. NFC involves hardware and software designed with volume production in mind. NFC Solutions is built on highly scalable printed electronics technology. NFC features OpenSense™ Technology - Dual-ID tag with sealed/opened sensor. In addition, it features SpeedTap™ Technology - Single-ID tag.
Moreover, Thin Film’s products include EAS Tags. These are for retailers to strengthen their retail loss-prevention programs with next-generation anti-theft tags. The Company’s 8.2MHz tags are compatible with globally installed infrastructure. Integrated EAS maximizes product availability and minimizes loss. EAS Tags also reduce overhead associated with hard tag application and removal.
This past November, Thin Film announced it received the IDTechEx Technical Development in Manfacturing award in recognition of its pioneering roll-to-roll printed electronics fab in San Jose, California. The IDTechEx Awards were presented as part of the Printed Electronics USA 2018 conference. They recognize company development and success in the field of printed electronics.
The Technical Development in Manufacturing award recognizes the most significant development of a manufacturing device, process, or production plant in the industry over the last 24 months. Award recipients must demonstrate the optimization of a lab-scale or mass-scale production process through improving productivity, quality, reliability, uniformity, or scale.
Thin Film’s San Jose facility features a 22,000 sq-ft printed electronics factory, which is the world’s first production roll-to-roll (R2R) printed electronics line using stainless steel substrates. The design of the fab is for an annual production capacity of up to seven billion units. It is optimized to enable production of low-cost, mechanically strong devices enabling high-volume applications. This includes NFC (near field communication) for mobile marketing, authentication, as well as supply chain services.
Thin Film Electronics ASA (TFECF), closed Wednesday's trading session at $0.0203, up 53.7879%, on 101,440 volume with 5 trades. The average volume for the last 3 months is 17,158 and the stock's 52-week low/high is $0.006699999/$0.035.
Geospatial Corp. (GSPH)
Penny Sleuth, Micro Cap Research, InvestorsHub, Market Screener, 4-Traders, Morningstar, MarketWatch, PR Newswire, GuruFocus, HotStockChat, YCharts, Wallet Investor, SmallCapVoice, Trading View, The Street, last10k, and Simply Wall St reported earlier on Geospatial Corp. (GSPH), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.
Geospatial Corp. is a leading innovator of asset management/analytics/mapping software and 3D mapping technologies. The Company utilizes integrated technologies to establish the accurate location and position of underground pipelines, conduits, and also other underground infrastructure data. This allows Geospatial to create accurate three-dimensional (3D) digital maps and models of underground infrastructure. Geospatial is headquartered in Sarver, Pennsylvania.
The Company has new Quality Assurance (QA) and Installed Locational Integrity Management (ILIM) programs for underground pipelines. Geospatial provides complete QA programs and ILIM programs for underground pipelines and conduits installed through Horizontal Directional Drilling (HDD) methods irrespective of depth, material, or soil conditions. The service addresses the need for accurate 3D mapping of critical pipeline segments, which exceeds regulatory requirements and supports integrity and reliability demands.
The Company provides integrated data acquisition technologies. These technologies accurately locate and map underground and aboveground infrastructure assets. This includes pipelines and surface features via Geospatial’s GeoUnderground Cloud-Based Portal. The design of GeoUnderground is around the Google Maps API.
GeoUnderground is the Company’s cloud-based Geographic Information System (GIS) platform. It provides clients with a total solution to their underground and aboveground asset management needs. Geospatial uses a collection of data acquisition tools. The Company cost-effectively maps most pipelines to an accuracy of less than 10 cm (3.9 inches).
GeoUnderground is a strong Cloud-Based GIS database. The database enables users to view and use this 3D pipeline mapping information securely from any desktop or mobile device. Geospatial is integrating Blockchain technology with GeoUnderground. This will provide a cloud-based locational software platform permitting energy companies a secure way to manage contracts, assure provenance, and track asset maintenance.
Recently, Geospatial announced that Kerr Engineered Sales and Geospatial entered into a sales and marketing agreement to provide underground mapping solutions, data acquisition and software solutions across the North East and Mid-Atlantic regions. Kerr Engineered Sales has been selling integrated solutions to major oil and gas transmission and distribution companies for decades. It has established a strong reputation representing many of the best technologies within the energy industry.
Geospatial Corp. (GSPH), closed Wednesday's trading session at $0.097, up 73.2143%, on 400 volume with 2 trades. The average volume for the last 3 months is 1,290 and the stock's 52-week low/high is $0.050099998/$0.200000002.
Escalon Medical Corp. (ESMC)
Stock Twits, Dividend Investor, Zacks, Morningstar, Market Screener, Simply Wall St, Wallet Investor, OTC Picks, MarketWatch, last10k, GuruFocus, Capital Cube, Stockhouse, last10k, Equity Clock, Wall Street Resources, FeedBlitz, PennyToBuck, 4-Traders, InvestorsHub, and YCharts reported previously on Escalon Medical Corp. (ESMC), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.
Escalon Medical Corp. specializes in the development, marketing, and distribution of ophthalmic diagnostic imaging and surgical products. It is working to grow its ophthalmic business through concentrating on its existing products, developing new products, utilizing strategic partnerships, and through acquisition.
Escalon Medical has its corporate headquarters in Wayne, Pennsylvania. The Company also has operations in Lake Success, New York; New Berlin, Wisconsin, and Stoneham, Massachusetts. Escalon Medical’s shares trade on the OTC Markets Group’s OTCQB.
Escalon Medical primarily markets to teaching institutions, hospitals, and eye surgery centers. The Company acquired Sonomed, Inc. in 2000. Since then, by way of acquisition, product divestitures, partnerships, and product development, it has grown and expanded its product offerings. Sonomed, Inc. and Escalon Medical Imaging are wholly-owned subsidiaries of Escalon Medical Corp.
Escalon Medical’s products include an assortment of ophthalmic ultrasound, digital imaging and photography, and image management systems. In addition, its products include surgical products, including intraocular gases, fiber optic light guides and sources, and other surgical vitreoretinal instruments.
All of the Company’s ophthalmic products are branded as Sonomed Escalon. Furthermore, Sonomed Escalon maintains certification for compliance with ISO1385 Quality Management Systems for Medical Devices.
Sonomed Escalon provides ultrasound, digital photography, and image management systems. Sonomed Escalon Rx products include mydriatics/cyclopegics; diagnostic supplies; anesthetics/combo products; antibiotics, steroid combination; injectable dyes, surgical products, and office products.
Concerning tonometry, Sonomed Escalon has its “diatom IOP measuring device.” This involves measuring IOP through the eyelid on sclera with no corneal contact. It rapidly provides accurate IOP reading independent of corneal thickness. Additionally, it is ideal for cases where standard tonometry cannot be used. No anesthesia is required and there is no need to remove contact lenses, no need for sterilization, and no patient discomfort or anxiety.
Moreover, surgical solutions offered include vitreoretinal gases and devices. Its diagnostic solutions include AXIS image management; ophthalmic ultrasound; mobile vision analysis; adaptive refractor; perimetry; digital imaging, and tonometry.
Sonomed Escalon offers its Vu Pad pertaining to Ophthalmic Ultrasound. This is a new class of ophthalmic ultrasound versatility. Vu Pad is configurable with B-scan, A-scan, UBM or any combination.
Escalon Medical established in 1987. The Company sells its products to medical institutions by way of independent sales representatives, a network of distributors, and internal sales employees.
Escalon Medical Corp. (ESMC), closed Wednesday's trading session at $0.018, up 43.4034%, on 243,385 volume with 10 trades. The average volume for the last 3 months is 33,601 and the stock's 52-week low/high is $0.0102/$0.074900001.
Vilacto Bio, Inc. (VIBI)
OTC Markets and The Street reported on Vilacto Bio, Inc. (VIBI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Vilacto Bio, Inc. is a biotechnology company listed on the OTCQB. It has developed the now fully patented Lactoactive® (Lactoactive molecule). In numerous studies, Lactoactive® has demonstrated above average effect treating conditions such as inflammatory diseases, diabetes, psoriasis, skin aging, and skin issues in different levels. At present the Company’s products are available on the market as Vilact®.
Founded in 2013, Vilacto Bio is headquartered in New York, New York. The Company previously went by the name Zlato, Inc. It changed its name to Vilacto Bio, Inc. on April 4, 2017. The Company’s European Headquarters are in Næstved, Denmark. Its Research and Development (R&D) operations are in Lithuania.
Vilacto Bio’s goal is to be the leading biotechnology company centered on commercializing unique pharmaceutical cosmeceutical products formulated or reformulated with Lactoactive® as nanoparticle according to its patented properties. The Company’s aim is to further develop its Lactoactive® molecule for increasing the quality of its retail and medical skin cream products, as well as licensing out its Lactoactive® molecule for the pharmaceutical industry.
Lactoactive® is highly refined colostrum, developed to provide first-rate results for people needing healing or relief from a range of skin issues. Lactoactive® is a refined processing of colostrum combined with hyaluronic acid. Proteins in Vilact® survive longer without being degraded by enzymes. This enables them to work longer in the skin.
Vilacto Bio has its Vilact Cuticle cream product, developed in cooperation with Danish podiatrists. Lactoactive, the ingredient molecule in Vilact Cuticle cream, works to help with skin challenges. Danish podiatrists have demonstrated its use with faster patient recovery.
This past January, Vilacto Bio announced that it started development of the Vilacto Bio Skincare Knowledge Center. This is an online resource that will gather skincare knowledge, science, insights and tips from scientists, dermatologists, podiatrists and other specialists around the world.
The tips and guides presented in the Vilacto Bio Knowledge Center will be shared with industry magazines internationally, and also with Vilacto customers. The expectation is that the Vilacto Bio Knowledge Center will enhance dialogue among specialists and consumers, improve outcomes, and drive higher traffic to Vilacto Bio’s commercial web portal.
Vilacto Bio, Inc. (VIBI), closed Wednesday's trading session at $0.0002, up 100.00%, on 2,737,851 volume with 5 trades. The average volume for the last 3 months is 4,552,329 and the stock's 52-week low/high is $0.000099999/$0.084799997.
RedHawk Holdings Corp. (IDNG)
TopPennyStockMovers, Real Pennies, Greenbackers, Fast Money Alerts, Mad Money Picks, The Observer, Innovative Marketing, Penny Stock General, Stock Shock and Awe, PennyStocks24, and Hot Stock Profits reported earlier on RedHawk Holdings Corp. (IDNG), and we also report on the Company, here at the QualityStocks Daily Newsletter.
RedHawk Holdings Corp. is a diversified holding company listed on the OTC Markets. The Company, via its subsidiaries, engages in the sales and distribution of medical devices, sales of branded generic pharmaceutical drugs, commercial real estate investment and leasing, sales of point of entry full-body security systems, and specialized financial services. RedHawk Holdings was formerly Independence Energy Corp. RedHawk’s subsidiaries are RedHawk Medical, EcoGen Europe, RedHawk Energy Corp., and RedHawk Land & Hospitality. RedHawk Holdings is based in Louisiana.
RedHawk Energy holds the exclusive U.S. manufacturing and distribution rights for the Centri Controlled Entry System. This System is a unique, closed cabinet, nominal dose transmission full body x-ray scanner.
Through its RedHawk Medical Products business unit, RedHawk Holdings sells WoundClot Surgical - Advanced Bleeding Control; the Sharps and Needle Destruction Device (SANDD™); the Carotid Artery Digital Non-Contact Thermometer, and Zonis®.
RedHawk Medical Products UK Limited is a specialist medical device company. It delivers innovative product solutions to healthcare markets in the United Kingdom (UK), Europe and the Middle East.
EcoGen Europe’s dedication is to healthcare and the NHS. Its commitment is to securing savings across the drug budget in primary care. This is while providing innovation to drive patient care in the acute setting. Last month, RedHawk Holdings announced that it recently completed its financial and legal due diligence and upon execution of final agreements, it will increase its ownership interest in EcoGen Europe to 75 percent.
RedHawk’s financial services revenue is from brokerage services earned in association with debt placement services and investments in oil and gas exploration and production. The Company’s real estate leasing revenues come from varied commercial properties under long-term lease. Moreover, its real estate investment unit holds limited liability company interest in different commercial restoration projects in Hawaii.
EcoGen Europe has signed an exclusive agreement to license and supply a new non-patent infringing generic spray formulation of Sildenafil Citrate in the UK. EcoGen will market the new spray under the brand name Azulvig. EcoGen expects to start marketing Azulvig after receipt of final UK regulatory approval.
RedHawk Holdings has acquired a stake in Tigress Energy Partners. RedHawk agreed to acquire up to a 25 percent interest in Marlin USA Energy Partners, LLC, the minority owner of Tigress Energy Partners, LLC (TEP). The majority ownership of TEP is held by Tigress Holdings, LLC, a limited liability company majority-owned by Cynthia DiBartolo, Chief Executive Officer of Tigress Financial Partners LLC (TFP).
RedHawk Holdings has also completed the re-engineering of its Sharps and Needle Destruction Device (SANDD). It received pre-market clearance from the U.S. Food and Drug Administration (FDA) for the sale of SANDD in the U.S. RedHawk Medical Products acquired the tangible and intangible property rights to SANDD (formerly known as the Disintegrator™ Insulin Needle Destruction Unit) in December 2015.
In early August, RedHawk Holdings announced that its wholly-owned real estate subsidiary, RedHawk Land & Hospitality LLC, entered into new agreements for the lease of its two commercial properties in Lafayette, Louisiana. The Company said it entered into a new triple-net lease agreement with the Louisiana 3rd Circuit Court of Appeal to renew and extend the present lease term to December 31, 2022. The new lease agreement was effective August 1, 2017 and included certain rate increases.
RedHawk Holdings Corp. (IDNG), closed Wednesday's trading session at $0.024, up 129.6651%, on 61,579 volume with 14 trades. The average volume for the last 3 months is 19,275 and the stock's 52-week low/high is $0.009999999/$0.158999994.
The QualityStocks Company Corner
- Plus Products Inc. (CSE: PLUS) (OTCQB: PLPRF)
- Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX)
- The Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF)
- Earth Science Tech, Inc. (ETST)
- Nightfood Holdings, Inc. (OTCQB: NGTF)
- Grapefruit Boulevard Investments Inc. (IGNG)
- SinglePoint, Inc. (SING)
- Pressure BioSciences Inc. (PBIO)
- INmune Bio Inc. (NASDAQ: INMB)
- Youngevity International, Inc. (NASDAQ: YGYI)
- Willow Biosciences Inc. (CSE: WLLW)
- Sproutly Canada, Inc. (CSE: SPR) (OTCQB: SRUTF) (FRA: 38G)
- VPR Brands, LP (VPRB)
- Spectrum Global Solutions, Inc. (SGSI)
Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)
Plus Products Inc. (CSE: PLUS) (OTCQB: PLPRF) (the “Company” or “PLUS”) today announced that it has launched its first California-wide marketing campaign with billboards and other out-of-home media secured in highly trafficked areas across San Francisco, Los Angeles and San Diego. Also today, NetworkNewsWire released a report on the company detailing how PLPRF is committed to ensuring the consistency of its products as it expands and sees continued success in the industry. PLUS co-founder and CEO Jake Heimark recently reiterated the company’s commitment to maintaining quality and consistency in PLUS products, wherever they are sold (http://nnw.fm/4rAW0).
Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.
First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.
PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.
Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.
During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:
- Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
- Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
- Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
- Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
- Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
- Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.
“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”
The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.
Plus Products Inc. (PLPRF), closed the day's trading session at $0.22, up 15.79%, on 13,350 volume with 5 trades. The average volume for the last 3 months is 12,195 and the stock's 52-week low/high is $0.125/$0.59.
- PLUS Products Kicks off Advertising Campaign Across California
- Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) Committed to Product Consistency, Quality for Cannabis Edibles Brand
- Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) Launches Microdosing Mints, Evaluates Acquisition
Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX)
Automotive technology innovator Foresight Autonomous Holdings (NASDAQ: FRSX) (TASE: FRSX) this morning announced an additional sale of a prototype of its QuadSight(TM) four-camera vision system that targets the semi-autonomous and autonomous vehicle market. To view the full press release, visit: http://nnw.fm/xg8VR.
Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX), founded in 2015 and headquartered in Israel, is a technological innovator in automotive vision systems and driver assistance technology. Through its wholly owned subsidiary, Foresight Automotive Ltd., Foresight is engaged in the design, development and commercialization of stereo/quad-camera vision systems and V2X cellular-based solutions for the automotive industry based on 3D video analysis, advanced algorithms for image processing and sensor fusion. The company’s powerful and patented stereoscopic technology is derived from field-proven technology that has been deployed throughout the world for almost two decades.
Foresight’s innovative autonomous driving solutions are based on mature, proprietary stereoscopic image technology that uses two synchronized cameras to mimic human depth perception and produce a three-dimensional image. This 3D image can anticipate possible collisions with other vehicles, cyclists, pedestrians and other obstacles. The technology provides highly accurate real-time alerts about the vehicle’s surroundings while in motion. The systems are designed to improve driving safety by enabling highly accurate and reliable threat detection while ensuring the lowest rates of false alerts.
The company’s patents provide IP protection for its robust and proven proprietary stereoscopic technology, which was developed using the security technology of Foresight’s major shareholder, Magna B.S.P.
Foresight has developed three main products:
- QuadSight™. This breakthrough detection system sets the bar for autonomous vehicle vision. It features nearly 100 percent obstacle detection with almost zero false alerts and operates optimally under all weather and lighting conditions, including darkness, rain, fog, haze and glare. QuadSight™ is the first quad-camera multi-spectral vision solution of its kind, driven by advanced and proven image processing algorithms. The system consists of two sets of stereoscopic infra-red and visible-light cameras that enable highly accurate and reliable obstacle detection for seamless 24/7 vision.
- Eyes-On™. This solution uses advanced algorithms for accurate depth analysis and obstacle detection to provide a unique stereo vision Advanced Driver Assistance System (ADAS). It can detect all potential obstacles regardless of shape, form or material, including other vehicles, cyclists, pedestrians and animals. It has an accuracy and reliability of almost 100 percent and near zero false alerts.
- Eye-Net™. This is a cellular-based accident prevention solution that is designed to provide real-time pre-collision alerts to vehicles and pedestrians. This proprietary system is deployed on smartphones and cloud-based servers operating on existing cellular networks, and it eliminates the need for additional designated hardware. Eye-Net™ is designed to provide a complementary layer of protection to advanced driver assistance systems and extends this protection to road users who are not in direct line of sight. It is optimally designed for both urban environments and high-speed scenarios to provide protection for the most vulnerable road users. On March 28, 2018, Foresight announced that it had completed a successful feasibility study of its Eye-Net™ accident prevention solution involving 120 users of Android and iOS cell phones located across Israel.
In 2017, Foresight sought more opportunities within the international market. The Company signed pilot agreements with three leading car manufacturers in China and completed pilot projects meeting all pre-defined requirements and criteria. In addition, FRSX completed a pilot project with Uniti Sweden.
Studies by the Insurance Institute for Highway Safety continue to emphasize the dramatic reduction in accidents and injury-related crashes reported when vehicles are equipped with collision avoidance systems. A recent study by the Institute states that the rate of single-vehicle, sideswipe and head-on crashes was 11 percent lower in vehicles with the warning systems. More importantly, the study shows collision avoidance technology cut the rates of injury crashes of the same type by 21 percent.
Foresight Autonomous Holdings, Inc. also holds a 32 percent interest in RailVision, a company that develops advanced systems for railway safety and maintenance. RailVision has successfully completed 13 tests in Israel, Germany, Italy and Switzerland in addition to a real-time system test with a European railway operator. Over the course of 2017, RailVision successfully completed rounds of financing totaling $5.8 million and started the process of licensing the system according to European standards.
Haim Siboni is the founder of Foresight and has served as the company’s chief executive officer and director since 2015. Siboni, a passionate entrepreneur, has an extensive background in the marketing and business management sectors in the fields of electronics, video, TV, multimedia, computerized systems, line and wireless telecommunication, design and development of systems and devices, including electro-optic radar systems. He is the founder and CEO of Magna B.S.P., Foresight’s major shareholder and a leading innovator in the field of homeland security surveillance solutions.
Foresight Autonomous Holdings Ltd. (FRSX), closed the day's trading session at $0.109, up 21.11%, on 240,000 volume with 13 trades. The average volume for the last 3 months is 32,423 and the stock's 52-week low/high is $0.0075/$0.105.
- Foresight Autonomous Holdings Ltd.’s (NASDAQ: FRSX) (TASE: FRSX) QuadSight(TM) Prototype Ordered by American Subsidiary of Leading Global Supplier
- Foresight Receives Order of QuadSight™ Prototype from Leading Japanese Tier One Supplier
- Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX) Subsidiary to Conduct Five Day Trial of Cellular-Based Accident Prevention Solution
The Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF)
Supreme Cannabis Company (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) on Wednesday announced the appointment of its new Chief Information Officer ("CIO") Ash Rajendra, who will focus on ensuring the company is well prepared to execute on its next phase of growth. In addition, Supreme Cannabis announced that Valerie Rother has joined the company and will serve as its new VP, Talent, to steward its human capital and talent development program. To view the full press release, visit: http://nnw.fm/z6U4T.
Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF), is committed to providing premium brands and products that reflect the company’s knowledgeable customers, passionate employees, and culture of innovation. Supreme Cannabis’ mission is to grow the world’s best cannabis and become a leader in the global industry. The company calls its Toronto Venture Exchange stock symbol FIRE “a testament to our passion for cannabis and our obsession with quality.”
Supreme Cannabis believes the world is ready to follow Canada’s lead by ending the 100-year cannabis prohibition and, as Canada’s only coast-to-coast premium cannabis producer, the company sees itself at the center of this global shift.
In August 2018, Supreme Cannabis uplisted its shares to the to OTCQX market in the U.S., where the company trades under the ticker symbol SPRWF. The following month Supreme reported record Q4 revenues of CAD$3.55 million, a 71-percent increase over the previous quarter. Supreme Cannabis also recorded revenue of CAD$8.85 million for its fiscal year ended June 30, 2018, placing it among publicly traded Canadian cannabis companies with the highest reported revenue in their first four quarters of sales.
“As a result of the successful execution of our strategy, we have generated significant revenue growth both for the quarter and the year-end period,” Supreme Cannabis CEO Navdeep Dhaliwal stated in a news release. “We look forward to building on this growth as we expand domestically and internationally.”
The company’s growth strategy includes key industry agreements, such as its CAD$12 million supply agreement with Tilray Inc. (OTC: TLRY), a global leader in cannabis research, cultivation, processing and distribution. The agreement calls for Supreme to supply Tilray with dried cannabis for support of medical cannabis patients in Canada for the period of one year.
Another key component is the company’s wholly owned 7ACRES subsidiary. The 7ACRES cultivation facility, one of the first 40 federally licensed cannabis producers in Canada, is focused on building a core competency in scaled cannabis production, which will give 7ACRES the needed flexibility to maintain leadership in the industry as the Canadian market grows and matures. Though 7ACRES is Supreme Cannabis’ flagship brand and only currently operating business unit, the company will continue to identify new opportunities to grow its portfolio of companies and build innovative cannabis businesses throughout the world.
7ACRES operates from a 342,000-square-foot cultivation facility in Kincardine, Ontario, and has been federally licensed since 2016. Current capacity is 13,333 kilograms dried cannabis annually, with plans to ramp up production by mid-2019 to a rate of 50,000 kilograms per year.
Supreme Cannabis seeks to differentiate 7ACRES from other licensed cannabis producers by producing premium quality product sustainably at scale. “Craft quality, commercial scale” is a slogan the company uses, and the Kincardine greenhouse employs state-of-the-art technology and cultivation best practices to strive toward that goal. Supreme identifies the quality of the 7ACRES product as the company’s primary strength and says a shared “passion for the plant” is the driver of company culture. Six Canadian provinces have signed supply agreements with Supreme, a fact the company credits to the high quality of 7ACRES cannabis.
Its customers, Supreme Cannabis management says, are informed and discerning regarding cannabis, and they value a premium brand that respects their product knowledge. The company believes its high regard for customers, premium product quality, and mass cultivation capability has allowed Supreme Cannabis to emerge as Canada’s preeminent premium cannabis producer. In the Canadian cannabis market, the company has established 7ACRES as a premium brand that’s distributed coast-to-coast and commands premium pricing. The 7ACRES brand is already listed as premium cannabis product in all provinces that disclose their cannabis listing categories, and 7ACRES on average wholesales for up to one-third higher in price than other brands in the Canadian cannabis market.
To further its distribution, in the medical cannabis market Supreme Cannabis has partnered with several Canadian cannabis retailers including Aurora Cannabis, Emerald Health Botanicals, Namaste, Zenabis, and others. The company’s investment portfolio also includes an equity position and long-term global distribution partnership with Medigrow, based in Lesotho, targeting the export of medical cannabis oil for the international market.
Supreme Cannabis seeks to make the company an innovator in the cannabis sector regarding design of cultivation facilities and development of operation excellence metrics. The management team is confident that the 7ACRES flagship brand, the company’s proprietary technology and products, and the company’s culture of passion for cannabis will deliver consistent long-term shareholder value.
Supreme Cannabis Company Inc. (OTC: SPRWF), closed the day's trading session at $3.60, up 34.83%, on 3,388,904 volume with 4,979 trades. The average volume for the last 3 months is 1,322,318 and the stock's 52-week low/high is $1.87/$7.89.
- Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) Expands Executive Team; Appoints New Chief Information Officer and VP of Talent
- Supreme Cannabis Appoints New Chief Information Officer and VP of Talent
- Supreme Cannabis Company Inc.’s (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) New Investment Platform Targets UK, European CBD Health and Wellness Sector
Earth Science Tech, Inc. (ETST)
Earth Science Tech Inc. (OTCQB: ETST), headquartered in Doral, Florida, is an innovative biotech enterprise that offers CBD in the forms of vitamins, minerals, herbs, botanicals, personal-care products, homeopathies, functional foods and other products. Through its wholly owned subsidiaries, the company operates in the fields of hemp cannabinoids, nutraceuticals, pharmaceuticals, medical devices, and research and development.
Earth Science Tech, Inc. (ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.
Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:
- Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
- Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
- KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.
Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.
In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.
The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.
Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.
Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.
The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.
Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.
Earth Science Tech, Inc. (ETST), closed the day's trading session at $0.0137, off by 6.36%, on 5,992,366 volume with 158 trades. The average volume for the last 3 months is 10,958,619 and the stock's 52-week low/high is $0.0123/$0.16.
- Earth Science Tech Inc. (ETST) Strengthens Foothold in Global CBD Arena
- Earth Science Tech Inc. (ETST) Stock Evaluated by InvestorPlace Analyst
- Earth Science Tech Inc. (ETST) Reports 66.4% Increase in Sales, 52.9% Jump in Gross Profits
Nightfood Holdings, Inc. (OTCQB: NGTF)
Nightfood, Inc. (OTCQB: NGTF), the fast-growing, award-winning ice cream company addressing America's $50 billion-dollar nighttime snacking opportunity, announced today that Sean Folkson, Nightfood CEO, will present live at VirtualInvestorConferences.com on Thursday, August 1, 2019.
Nightfood Holdings, Inc. (OTCQB: NGTF), a pioneering consumer goods brand development company headquartered in Tarrytown, New York, owns Nightfood, Inc., creator of delicious, award-winning and better-for-you ice cream formulated by sleep and nutrition experts, and its wholly owned subsidiary MJ Munchies, Inc., which seeks to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. Known as “The Nighttime Snack Company,” Nightfood Inc. is focused on improving the late-night snacking choices of consumers while solving America’s $50 billion-dollar nighttime snacking problem.
Nightfood Ice Cream
Nightfood’s higher-protein and sleep-friendly ice cream won the 2019 Product of the Year Award in a survey of over 40,000 consumers. The annual Product of the Year survey, the world’s largest consumer-voted award for product innovation, is conducted by Kantar, a global leader in consumer research. In beating out the other finalists, consumers indicated that Nightfood’s one-of-a-kind innovation and unique value proposition made it a clear-cut winner in the ice cream space and a brand they were highly motivated to try. Winners of the 32-year-old award have been shown to outperform category sales performance by over 38 percent.
Less than two months since manufacturing their first pint of ice cream, Nightfood has now secured distribution in more than 13 states, and has received extensive media coverage from outlets such as USA Today, Fox Business’ Mornings With Maria, Parents Magazine, The Food Network, MarketWatch, The Washington Post, Business Insider, Bustle, and more.
With the Product of the Year award and millions in media coverage, Management has publicly stated their goal of securing nationwide distribution in over 10,000 retail outlets by March 31, 2020.
Formulated by leading sleep and nutrition experts, including America’s most prominent sleep expert, Dr. Michael Breus, Nightfood’s higher protein/higher fiber, and lower sugar ice cream delivers great ice cream taste and texture, while minimizing sleep-disruptive ingredients such as caffeine, excess sugar, and excess fat and calories. The addition of certain minerals, enzymes and amino acids, which research suggests can support sleep quality, is another bonus. Nightfood only uses hormone-free milk, is certified Kosher, and offers eight original flavors, five of which are gluten-free. Nightfood ice cream also uses all-natural sweeteners with no Erythritol, no sucralose, or other artificial sweeteners.
More than 37,000 consumers across the country have already requested coupons for the company’s newly launched Nightfood ice cream by entering a giveaway hosted at NightfoodIceCream.com which includes a chance to win a one-year supply (96 pints) plus a freezer for storage. The coupon program is being run in conjunction with PromotionPod, which has previously conducted successful campaigns for brands such as Chobani, Halo Top, and BodyArmor.
Nightfood Inc. began its nationwide rollout of Nightfood ice cream in February 2019, successfully securing placement in Meijer supermarket locations in the Midwest with a concentration around the metropolitan areas of Chicago, Detroit, Indianapolis, Columbus and Milwaukee. A distribution agreement with New England Ice Cream Corporation (NEIC) will also place Nightfood ice cream in outlets located throughout Massachusetts, Vermont, New Hampshire, Maine, Rhode Island and Connecticut.
Ice cream lovers in northern California will find Nightfood Ice Cream at various upscale, independent retail outlets in and around the San Francisco bay area serviced through a distribution agreement with Wonder Ice Cream Company, which services thousands of retail outlets from Bakersfield north to the Oregon border. Consumers can also purchase Nightfood ice cream online at BuyNightfood.com through the Company’s partnership with IceCreamSource.com.
Ice cream is now the 2nd most popular night snack choice, with almost half of all consumers reaching for ice cream after dark. According to IRI Worldwide, 44 percent of all snack consumption occurs between dinner and bedtime, representing a consumer spend of over $1 billion weekly on nighttime snacks in the U.S. alone. Market research giant Mintel recently released a report identifying nighttime specific food and beverages as one of their most “compelling and category changing” trends for 2017 and beyond.
Nightfood has developed a dynamic infographic resource that clearly illustrates the size and scope of the largely untapped nighttime snack category (http://NightSnacking.com). Americans everywhere are likely to identify with the infographic’s results that vividly illustrate late night snacking by age group, popular snack choice, and amount of money spent each week on feeding after-hour snack attacks. Available in eight delicious flavors, Nightfood ice cream can help consumers satisfy nighttime cravings in a better, healthier, more sleep-friendly way.
MJ Munchies, Inc.
MJ Munchies, Inc., was formed in 2018 as a new, wholly owned subsidiary of Nightfood Holdings, Inc. to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. The Company intends to market some of these new products under the trademarked brand name “Half-Baked” and has entered into a Letter of Intent that allows Global Consortium Inc. (OTC: GCGX) subsidiary Infused Edibles to receive an exclusive license to manufacture and distribute marijuana and CBD-infused products under the Half-Baked brand.
Management believes the Half-Baked brand will give the Company a unique and defensible competitive advantage against other recreational edible brands. The Company believes tremendous opportunities currently exist to launch successful and legally compliant products in this space, and that such opportunities will continue to grow over time.
Nightfood founder and CEO Sean Folkson is a formerly frustrated nighttime snacker whose late-night cravings led him to seek a better solution for himself and others through the creation, marketing and distribution of the Nightfood product line. Folkson also founded internet marketing company AffiliatePros.com which provided the startup capital to launch Specialty Equipment Direct, an online distributor of floor removal equipment that quickly grew to 7-figure revenues. Folkson received a bachelor’s degree in business administration with a concentration in marketing from S.U.N.Y Albany, New York, in 1991.
Jim Christensen, vice president of Nightfood Ice Cream, is the former Vice President of Ice Cream Sales with global ice cream giant Unilever. In his over 20 years at Unilever, Jim led sales and distribution initiatives for brands such as Ben & Jerry’s, Klondike, Breyers and Good Humor. Christensen joined the Nightfood team in June of 2018 with the directive to launch Nightfood ice cream rapidly into national distribution through supermarket, drug, convenience and other channels. Understanding that the overwhelming majority of at-home ice cream consumption occurs in the hours before bed, Christensen has identified Nightfood as the next evolution in better-for-you ice cream.
CFO Mark Noffke, CPA, has over 37 years of experience as a seasoned financial and management professional. He has served as chief financial officer of several small cap public companies since 2004 where he oversaw virtually every aspect of the company’s operations, administration, customer service and human resources. Noffke has a bachelor’s degree in accounting from Valparaiso University in Indiana.
The Nightfood advisory board includes Tom Morse, founder of 5-Hour Energy and Living Essentials, LLC.; Doron Stern, former vice president of marketing at Chobani and Popcorn, Indiana; restaurateur and celebrity Chef Chris Santos; Paul Jarrett, CEO of fast-growing nutrition startup BuluBox; Eric Egeland, president of Capacity Consulting Inc.; Dr. Michael A. Grandner, director/Sleep and Health Research Program at the University of Arizona; Dr. Michael Breus, sleep expert and best-selling author known to millions as The Sleep Doctor(TM); Dr. Lauren Broch, resident nutrition, sleep disorder expert and a member of the scientific advisory board.
Nightfood Holdings, Inc. (NGTF), closed the day's trading session at $0.01463, up 5.25%, on 11,099,794 volume with 244 trades. The average volume for the last 3 months is 10,992,233 and the stock's 52-week low/high is $0.0123/$0.16.
- Nightfood to Present at VirtualInvestorConferences.com on August 1, 2019
- Nightfood® Sleep-Friendly Ice Cream Featured in Oprah Magazine July Issue
- Nightfood Holdings Inc. (NGTF) Beyond Food-Organic and Healthier Food Trends 2019
Grapefruit Boulevard Investments Inc. (IGNG)
Grapefruit Boulevard Investments Inc., a California corporation and a wholly owned subsidiary of Imaging3 Inc. (OTCQB: IGNG), has entered into a letter of intent with Dogwood Management Group Inc. The nonbinding letter of intent outlines the agreement between the two companies: Grapefruit plans to acquire and Dogwood will manage California-licensed and fully compliant retail cannabis dispensaries throughout California that meet the regulatory, operational and financial results requirements for the two companies (http://nnw.fm/tPxN4).
Grapefruit Boulevard Investments Inc., a California corporation (“Grapefruit”), as of May 31, 2019, is a wholly owned subsidiary of Imaging3 Inc. (OTC: IGNG), a Delaware corporation whose shares of $.001 par value common stock are publicly traded on the OTCMarkets OTCQB Market under the symbol “IGNG.” IGNG is subject to the reporting requirements of the Securities Exchange Act of 1934 and files annual and quarterly reports pursuant thereto. Grapefruit holds licenses originally issued by the State of California in January 2018 to both manufacture and distribute cannabis products. Grapefruit’s management now owns a controlling interest in IGNG which now owns 100% of Grapefruit’s outstanding shares. As a result, IGNG’s financial reports will consolidate both IGNG’s and Grapefruit’s balance sheet, statement of operation and statement of cash flows and IGNG and Grapefruit will be operated as a single company. IGNG intends to change its name to Grapefruit and to obtain a more appropriate trading symbol as soon as possible. Hereinafter the combined companies will be referred to as “Grapefruit” or the “Company.”
Grapefruit’s corporate headquarters is in Westwood, Los Angeles, California. Grapefruit holds licenses to both manufacture and distribute cannabis products which were originally issued in January 2018 and is fully compliant with all applicable laws and regulations to operate its cannabis manufacturing and distribution businesses.
The company is well-focused on sourcing only the “best of the best” raw cannabis materials to create the highest quality, most-trusted and consistent recreational and medical cannabis products for its customers. Grapefruit is committed to ensuring class-leading quality by rigorously testing the purity and potency of its raw materials throughout the manufacturing process and distribution chain.
Grapefruit owns and operates its fully licensed and compliant ethanol extraction laboratory located in the Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park in Desert Hot Springs, California. The company’s extraction lab produces high quality, cannabis-derived distillate, also known as “honey oil,” from cannabis flower and “trim.” THC honey oil is one of base cannabis commodities which serves as the active ingredient in everything from infused edibles and tinctures/creams to the cartridges used in vapes and e-cigarettes. Honey oil often sells on the wholesale marketplace for thousands of dollars per liter, with pricing being dependent on quantity purchased, as well as other market factors such as the availability and cost of the underlying flowers and/or trim.
Grapefruit began its extraction operations in May 2019. Plans are in place to expand its honey oil production through the purchase of additional distillation equipment, which is expected to significantly increase the company’s production capacity by the fourth quarter of 2019. Grapefruit’s extraction lab is fully scalable and expansion will be built-out on a two-acre lot owned by Grapefruit at the Coachillin’ site adjacent to its current manufacturing and distribution operation.
Grapefruit selected the City of Desert Hot Springs for its cannabis extraction laboratory, because the city has created a friendly business environment for cannabis-based manufacturers, including incentives like the absence of taxes on cannabis oil production revenues. This affords Grapefruit a fundamental competitive market advantage over other Honey Oil producers.
The California cannabis regulatory scheme is unique in that it requires all cultivators (cannabis farms) and manufacturers (whether producing oils/distillates, infused edibles, tinctures creams or other cannabis products) to sell their products into the legal cannabis wholesale and retail markets exclusively through licensed distributors such as Grapefruit. Grapefruit initially obtained its California recreational and medicinal cannabis distribution license Jan. 4, 2018. In May 2019, Grapefruit was granted its provisional distribution license which is renewable annually, thereby cementing the regulatory foundation necessary to rapidly expand its distribution business.
Grapefruit’s distribution license affords it a twofold strategic advantage: first, to market and sell its own cannabis product lines to retailers throughout California; and second, to buy and resell bulk cannabis flowers and trim as well as all other legal cannabis products to properly licensed distributors and/or retailers throughout California.
The Coachillin’ Canna-Business Park, home to Grapefruit’s current operating facilities and adjacent two-acre parcel of land, is a 160-acre, self-contained legally mapped compound providing the Company with a fully permitted and serviced physical plant from which Grapefruit intends to establish a leading position in the booming California cannabis sector. The parcel was purchased by the Company prior to the Park’s full development, and the value of the land the Company owns has conservatively since doubled in value to over $2 million. Additional long-term benefits of the Coachillin’ compound include agricultural rates for power, which are currently $0.09 per kilowatt hour; the Park’s deep-water well that fully satisfies its need for water; and security expenses shared by all resident businesses. The Coachillin’ Park’s promoters also plan to position the Park, located only 10 miles north of rapidly growing uptown Palm Springs and less than 15 miles from the site of the Coachella and Stagecoach music festivals as a must-see canna-tourism destination.
Grapefruit’s ultimate goal is to become a vertically integrated, seed-to-sale cannabis and CBD product company serving the California market. Moreover, it plans to roll-out its product lines in other states, such as Nevada, Illinois, Oregon, Colorado and Washington. Grapefruit has plans to build a large, all-inclusive facility that will house a 50,000-square-foot-plus indoor grow canopy, a large extraction laboratory designed to extract both THC and CBD cannabinoids via non-volatile (ethanol) and volatile (butane) processes, a manufacturing space to produce Grapefruit’s vape lines and CBD products, an FDA-certified kitchen for the production of Grapefruit edibles and a distribution facility to sell all products into the entire cannabis market. The indoor grow canopy operation will be outfitted and operated to produce ultra-high-quality flowers and buds, some of which, along with the high-quality trim resulting from cleaning and maintaining the grow, will provide biomass necessary to feed the company’s extraction laboratory. Fueled by this hand cultivated biomass, Grapefruit’s lab will continuously produce pesticide and heavy metal-free world class honey oil to both serve as the active ingredient in all of Grapefruit’s branded and unbranded products and meet the projected ever-growing demand for high quality honey oil in the California market.
Grapefruit’s motto – A High You Can Trust – embodies its philosophy and ethos, reminding consumers of the company’s commitment to manufacturing, procuring and distributing only the highest quality all-natural cannabis flower, concentrates and related products that are free from pesticides, heavy metals and bacteria. Grapefruit will target its products to all recreational cannabis enthusiasts’ as continuous, consistent cannabis products. By relentlessly adhering to these policies Grapefruit intends to become the Titleist of the Cannabis industry, known for unwavering quality and consistency.
Grapefruit is managed by a team of experts possessing the experience, skill and resources required to succeed in the competitive cannabis marketplace. Founded by brothers Bradley Yourist, CEO, and Daniel Yourist, COO, Grapefruit has expanded to become a group of industry professionals sharing a passion for all things cannabis. Both the CEO & COO are attorneys licensed to practice law the State of California who possess expert cannabis licensing and regulatory expertise and experience, which will allow Grapefruit to deftly navigate the ever changing California regulatory landscape and apply for new cannabis licenses at reduced costs when necessary, rather than having to acquire licenses that are often overvalued and/or pay outside counsel to handle such matters.
Grapefruit also has its own line of cannabis-infused concentrates and edibles. Among the brands now in stores or soon to be launched are:
- Rainbow Dreams is a new lifestyle brand designed specifically for the recreational cannabis marketplace. The Rainbow Dreams brand captures the anything goes party vibe of the 1970s by offering an array of cannabis products, such as a line of vape carts with unique cannabis strains combined with all-natural flavors for a superior no-burn experience. Rainbow Dreams fills an important niche in the marketplace as a top shelf quality product line that is competitively priced.
- Sugar Stoned, which Grapefruit acquired in the winter of 2018, has always been a popular cannabis edibles brand which terminated operations when recreational cannabis became legal and required a license in California. Grapefruit purchased the Sugar Stoned brand in 2019 and it is now a Grapefruit portfolio brand consisting of a premium quality cannabis-infused gummy line with eight different flavors: blue raspberry, cherry, grape, peach, pineapple, sour apple, strawberry and watermelon. Grapefruit intends to expand the brand in the near future through the release of a variety of infused cookies.
Grapefruit Boulevard Investments Inc. (IGNG), closed Thursday's trading session at $3.25, up 1.8809%, on 9,219 volume with 35 trades. The average volume for the last 3 months is 9,006 and the stock's 52-week low/high is $1.51999998/$4.0999999.
- Grapefruit Boulevard Investments Inc. (IGNG) to Acquire Premier Retail Dispensaries in Expanding California Cannabis Marketplace
- Coverage Initiated for Grapefruit Boulevard Investments via NetworkNewsWire
- Grapefruit Boulevard Investments Inc. (IGNG) is “One to Watch”
SinglePoint, Inc. (SING)
Technology and investment company SinglePoint (OTCQB: SING), together with its subsidiary Direct Solar, today announced the addition of a new arm, Direct Solar Capital, an alternative energy financing solution. “We are looking for any developers, manufacturers, EPCs, contractors, etc. that have an alternative energy project that is ready to go, and they just need financing,” Pablo Diaz, CEO of Direct Solar of America and Direct Solar Capital, said in the news release. To view the full press release, visit: http://nnw.fm/Rq2d8.
SinglePoint, Inc. (SING) is a diversified holding company with operations in multiple industries and verticals including two high-performing market sectors: legal cannabis and cryptocurrencies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.
SinglePoint is researching opportunities where it can be an active participant by influencing the strategy and direction of high-potential companies whose verified assets offer attractive possibilities for shareholders. The company is guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital.
SinglePoint is bullish on the cannabis industry, bitcoin and blockchain technologies, which is evident in its recent acquisitions and joint-venture announcements. Recent SinglePoint key highlights include:
- A joint venture with Smart Cannabis Corporation (OTC: SCNA) to license and market Smart Cannabis’ SMART APP. SMART APP enables cannabis growers to measure all aspects of cultivation, from soil nutrient levels to watering cycles and carbon dioxide content in the air. SMART APP will integrate SinglePoint’s bitcoin payment solution to enable growers to process safer and more secure transactions.
- A joint venture with Global Payout (OTC: GOHE) will build on existing financial technology solutions developed by SinglePoint and Global Payout’s subsidiary MoneyTrac Technology, Inc., to fully optimize the delivery of mobile payment applications for domestic and international organizations.
- A joint venture with AppSwarm (OTC: SWRM) to start development on a proprietary delivery application that will enable licensed cannabis delivery services and licensed dispensaries to safely make in-home cannabis deliveries.
- Signed original “Shark Tank” member Kevin Harrington as company spokesman for an innovative, compatible virtual wallet to store any type of cryptocurrency. Harrington recently finished shooting a new national ad campaign featuring SinglePoint and the virtual wallet’s secure method of storing cryptocurrencies.
- Entered into a letter of intent to acquire 100 percent of Bitcoin Beyond, a premier platform that enables merchants to accept bitcoin payments using existing web-enabled point-of-sale devices.
- Through SING subsidiary, SingleSeed, the company will soon offer a proprietary cryptocurrency solution that links both cannabis merchants and consumers who seek to take advantage of bitcoin-powered transactions using debit and credit cards. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system deducts items automatically from a dispensary’s product listings when a purchase is made. While this fully KYC-AML compliant point-of-sale platform can be utilized for any other retail setting, it will fill a critical need in the underbanked cannabis industry as it continues to seek non-cash payment solutions outside of traditional banking circles.
SinglePoint CEO and founder Greg Lambrecht leads the company in its mission to capture opportunities through an aggressive expansion strategy across a broad range of assets. Lambrecht oversees all company operations including investor relations, leadership of the board of directors, and daily business activities. As the founder of PCI, a leading consumer product distribution company, Lambrecht negotiated agreements with the nation’s largest retail outlets and led PCI through a NASDAQ listed IPO, raising $10 million.
Eric Lofdahl, SinglePoint’s chief technology officer, has more than 20 years of experience in the technology sector including positions in software development, program management, complex system integration and engineering process definition. Prior to SinglePoint, Lofdahl worked at the Boeing Company where he led a team that successfully developed advanced wireless and satellite data products based on commercial technology for the U.S. Air Force.
SinglePoint President Wil Ralston is well known for his successful track record of building and maintaining great relationships with clients. Ralston graduated cum laude from the WP Carey School of Business at Arizona State University with a degree in Global Agribusiness and a specialization in Professional Golf Management. He is currently recognized by the Professional Golfers Association of America (PGA) as a Class A Professional.
SinglePoint, Inc. (SING), closed the day's trading session at $0.032, off by 5.88%, on 4,136,196 volume with 260 trades. The average volume for the last 3 months is 7,656,739 and the stock's 52-week low/high is $0.0132/$0.415.
- SinglePoint, Inc. (SING) Subsidiary Adds Alternative Energy Financing Solution
- SinglePoint Inc. (SING) Focuses on New Technologies, Offers Diverse Opportunities
- SinglePoint, Inc. (SING) Subsidiary Direct Solar Achieves $3.4M in Contracts in Just 60 Days
Pressure BioSciences Inc. (PBIO)
Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, today announced the initial sale of its revolutionary BaroShear(TM) K45 processing system. To view the full press release, visit: http://nnw.fm/AE1bj.
Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.
The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.
Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”
Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.
The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.
Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.
This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.
The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.
Pressure BioSciences Inc. (PBIO), closed the day's trading session at $0.293, off by 0.03%, on 23,081 volume with 23 trades. The average volume for the last 3 months is 23,504 and the stock's 52-week low/high is $0.01/$0.80.
- Pressure BioSciences Inc. (PBIO) Announces First Sale of the BaroShear K45, A Revolutionary Water-Soluble CBD Manufacturing System
- Pressure BioSciences Inc. (PBIO) Announces Second Major Contract Utilizing its BaroFold Technology Platform
- Pressure BioSciences Inc.’s (PBIO) Flagship Barocycler 2320EXTREME Featured at International Conference in China
INmune Bio Inc. (NASDAQ: INMB)
INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that C.J. Barnum, Director of Neuroscience and R.J. Tesi, M.D., the company’s co-founder, and CEO, will present at the 17th Annual Congress of International Drug Discovery Science & Technology on July 26 in Japan.
INmune Bio Inc. (NASDAQ: INMB) is a diversified clinical-stage immunology company developing novel therapies that target distinct parts of a patient's innate immune system to fight disease. Drug candidates INKmune™ and INB03 may be used to treat cancer while XPro1595 targets neuroinflammation as a cause of Alzheimer's disease. INmune Bio's product platforms utilize a precision therapy approach to promote the body's innate immune response to treat unsolved problems in medicine.
INmune Bio is the first biotechnology company to close an initial public offering (IPO) in 2019 and commence trading on The Nasdaq Capital Market. The company also received a "Part the Cloud" award from the Alzheimer's Association in 2018 which included a $1 million grant to advance INmune Bio's XPro1595 drug candidate.
INmune Bio's product pipeline targets three segments of concern:
- Alzheimer's disease/dementia claims 5.5 million patients in the United States. INmune Bio views Alzheimer's as an immunologic disease which changes the drug discovery process, changes the way clinical trials are designed, and may provide hope for patients and caregivers.
- Cancer residual disease which is expected to generate more than 1.7 million new cases yearly with an estimated 609,640 fatalities. INMB believe that converting resting Natural Killer ("NK") cells to primed NK cells, which kill cancerous cells on contact, is an important therapeutic strategy to help clear residual disease.
- Resistance to immunotherapy. By preventing the proliferation and function of cells that resist immunotherapy, patients should have a stronger immune response to cancer cells and may respond better to other cancer treatments including immunotherapy and live longer.
INmune Bio Drug Candidates and Clinical Programs
INKmune is a biologic delivery system that primes a patient's resting NK cells to kill cancer. INKmune targets residual disease for patients that have completed initial cancer therapy (surgery, radiation and/or chemotherapy) and have a low burden of disease with a high risk of relapse.
In late 2019, INKmune will start enrolling patients in a phase I/II trial for women with relapsed refractory ovarian cancer. In many patients, cancer relapse after seemingly effective cancer therapy is due to a failure of the patients own NK cells to eliminate minimal residual disease ("MRD").
Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells' ability to eliminate residual disease.
INB03 is a checkpoint inhibitor that targets myeloid derived suppressor cells ("MDSC") which can produce an immunosuppressive shield that prevents a patient's own immune system from attacking the cancer. INmune Bio is currently completing a monotherapy INB03 phase I trial in patients with advanced solid tumors. The INB03 program will transition into a combination therapy clinical program in the summer of 2019 to prepare for a phase II trial in patients resistant to checkpoint inhibitors due to increased MDSC.
Treatment with INB03 should eliminate MDSC in the tumor microenvironment to allow checkpoint inhibitors to be therapeutically effective.
XPro1595 targets the microglial immune cells of the brain that are activated in many Alzheimer's disease patients. These microglial cells are a cause of neuroinflammation that can kill nerve cells and promote synaptic dysfunction – the cause of dementia in Alzheimer's.
The three-month, phase I trial is expected to enroll 18 patients in summer of 2019. It is designed to measure traditional and novel biomarkers of inflammation in patients with mild to moderate Alzheimer's disease who have neuroinflammation. The trial is supported by a $1 million "Part the Cloud" grant from the Alzheimer's Association. Inflammation, especially chronic inflammation, is being recognized as an important part of the pathology of many diseases including cancer and Alzheimer's disease.
Dr. RJ Tesi, M.D., INmune Bio co-founder, CEO and acting chief medical officer, has been a licensed physician since 1982 and a Fellow of the American College of Surgery since 1991. He received his medical degree from Washington University School of Medicine in 1982 and has served many roles in several development-stage biotech companies focused on treatment of neurodegenerative diseases, hematologic malignancies, and other inflammatory diseases.
CFO David J. Moss co-founder, has been with the company since its formation in September 2015. He holds an MBA from Rice University and a bachelor's degree in economics from the University of California, San Diego. Moss has founded, funded and taken public various companies in a variety of industries since 1995.
Mark Lowdell, Ph.D. co-founder, has served as the chief scientific officer and chief manufacturing officer at INmune Bio since the company's formation. He is a professor of cell and tissue therapy at University College London where he has led a translational immunotherapy group since 1994. He has also been a director of cellular therapy at the Royal Free London NHS Foundation Trust. He received his Ph.D. in clinical immunology from London Hospital Medical College, University of London in 1992 and is a qualified immunopathologist.
Christopher J. Barnum is director of neuroscience at INmune Bio. Barnum is a neuroimmunologist with broad expertise across neurodegenerative and psychiatric diseases holding multiple positions in academic and industry. His focus has been on translating inflammatory therapies into clinical treatments for neurologic diseases using a biomarker-directed approach. Barnum's research has been supported by the NIH, the Michael J. Fox Foundation, and the Alzheimer's Association. He received his Ph.D. in neuroscience from Binghamton University.
INmune Bio Inc. (OTC: INMB), closed the day's trading session at $2.89, up 1.40%, on 662,692 volume with 1,103 trades. The average volume for the last 3 months is 1,204,327 and the stock's 52-week low/high is $1.607/$7.894.
- INmune Bio Co-Founder and CEO Presents at 17th Annual Congress of International Drug Discovery Science & Technology 2019
- NetworkNewsBreaks – INmune Bio Inc.’s (NASDAQ: INMB) Innovative Drug Candidate Targets Neuroinflammation to Treat Alzheimer’s Disease
- Alzheimer’s Disease Market Growth Driven by Innovative Developments Such as INmune Bio Inc.’s (NASDAQ: INMB) XPro1595
Youngevity International, Inc. (NASDAQ: YGYI)
Youngevity International Inc. (NASDAQ: YGYI) was featured today in the 420 with CNW by CannabisNewsWire. The registered medical marijuana caregivers in Michigan are authorized to grow more than a million cannabis plants, according to state statistics. This information is crucial as the state transitions from a purely medical cannabis program to one that embraces the recreational use of the drug by adults.
Youngevity International, Inc. (NASDAQ: YGYI) is a leading omni-direct lifestyle company offering a hybrid of the direct selling business model that includes e-commerce and the power of social selling. Among the Top 100 Global Direct Selling Companies, Youngevity offers products from the six top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, and a range of innovative services. Created through the 2011 merger of Youngevity Essential Life Sciences with Javalution® Coffee Company, today’s Youngevity International Inc. is a virtual worldwide Main Street of products and services under one corporate entity that supports a healthy and empowered lifestyle.
Youngevity International is dedicated to improving lifestyles through the universal desires of vibrant health and flourishing economics. Catering to health-conscious consumers, Youngevity believes that combining the best of the direct selling industry with the fundamentals and capabilities of a traditional business model will maximize shareholder value. The company’s Nutritional, Lifestyle and Telecommunications products and services are distributed through a global network of Preferred Customers and Distributors.
Youngevity’s wholly owned CLR Roasters LLC business line offers quality branded and private label coffee to retail stores, office coffee services, hospitality, food services, distributors, convenience, petrol stores and vending businesses. Today, CLR Roasters is the largest coffee provider for cruise lines in North America and the second largest roaster in the state of Florida. Producing a consistent premium product with superior taste, CLR Roasters has earned numerous certifications that demonstrate the company’s commitment to the craft of providing the highest quality coffee products using the best practice standards available.
Youngevity, operating in the direct-selling channel, is rapidly expanding its product and distributor base through acquisitions and mergers under an innovative concept called “the Network Cloud” that provides other direct selling companies with a home base. The company’s YoungevityGO2 mobile distributor app, a new technology-driven web platform supporting expansion of global e-commerce and social selling platforms, is available on Google Play and the App Store. In addition to the Network Cloud concept, Youngevity International owns CLR Coffee Roasters which operates a traditional coffee roasting business offering a JavaFit® gourmet product line that vertically integrates with Youngevity and its growing network of direct marketers.
Youngevity International offers more than 1,000 high quality, technologically advanced products under the following categories:
- Health and Nutrition
- Home and Family
- Food and Beverage
- Spa and Beauty
- Essential Oils
- Photo and scrapbooking
- Services for Home and Business
Youngevity International Inc. has compiled a best-in-class management team with a strong track record of success in private and public companies. Steve Wallach, CEO, has nearly two decades of sales and network marketing experience and has successfully guided Youngevity International Inc. to become an international, publicly-traded direct marketing company positioned for worldwide growth. Dave Briskie, president and CFO, has shepherded the company’s development into a fully vertical coffee roasting and distribution company that owns the direct marketing brand JavaFit® and the retail brand, Café La Rica.
Youngevity has also attracted a stunning group of Brand Evangelists who endorse its products. Among these are actress, author and well-known health and wellness activist Marilu Henner; former NBA basket player, Mike “Stinger” Glenn; former NFL wide receiver Drew Pearson; “Greatest Natural Bodybuilder in the World” Gene Nelson; and WNBA champion, Olympic gold medalist Delisha Jones.
Youngevity International, Inc. (NASDAQ: YGYI), closed the day's trading session at $2.91, up 8.38%, on 19,396 volume with 109 trades. The average volume for the last 3 months is 55,928 and the stock's 52-week low/high is $2.44/$8.20.
- 420 with CNW – Michigan Caregivers Grow More than a Million Marijuana Plants
- Youngevity Inc. (YGYI) Featured in CannabisNewsAudio Broadcast Featuring Potential Payoff in Back End of Cannabis
- Youngevity Inc. (YGYI) Featured in CannabisNewsWire Publication Discussing the CBD Industry’s ‘Sweet Spot’
Willow Biosciences Inc. (CSE: WLLW)
Willow Biosciences Corp. (CSE: WLLW) was featured today in the 420 with CNW by CannabisNewsWire. In August 2017, Andrew Brisbo, the Director of the Bureau of Medical Marijuana Regulation stated that approximately 43,000 patients had nominated a caregiver to grow a maximum of 12 cannabis plants for the medical use of the patient. That statistic means that approximately 1.14 million marijuana plants are under the direct control of the registered caregivers in the state. Currently, the number of caregivers on the medical marijuana program has risen to an estimated 47,000. This could mean that nearly 1.5 million cannabis plants are grown by these caregivers.
Willow Biosciences Inc. (CSE: WLLW) is a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates. The company’s cannabidiol (“CBD”) yeast-based biosynthesis program produces a high yield, ultrapure, low-cost and scalable manufacturing solution for pharmaceutical, food, beverage and personal care consumers of CBD.
The company is headquartered in Calgary, Alberta, Canada.
Willow’s proprietary yeast-based lab strains produce CBD, tetrahydrocannabinol (“THC”), and cannabigerol (“CBG”), as well as certain minor and novel cannabinoids.
The company’s expertise in the esoteric field of biosynthesis and in delivering commercial fermentation pathways for the production of pharmaceutical-grade compounds grew from its origins in opiate research. Willow recently delivered a de novo biosynthesis pathway in yeast for thebaine, a key precursor API used as a feedstock in the manufacture of semi-synthetic opiates such as naloxone (used to reverse opioid overdose) and several common analgesics. Led by Chief Scientific Officer Dr. Peter Facchini, Willow’s research team discovered and patented numerous previously unknown genes coding for core catalytic pathway enzymes, as well as a number of additional non-pathway, yet commercially-essential, accessory genes.
Utilizing this proven synthetic biology platform, Willow’s research team has already begun producing cannabinoids at lab scale, using yeast as the host cell “factory.” This biosynthetic fermentation-based process is capable of producing pharmaceutical grade CBD in 10 days – far less time than traditional plant-based extraction methods.
Willow anticipates its technology can be scaled to produce hundreds of kilograms per batch of cannabinoid API at less than $1,000 per kilogram, thus costing approximately 60% less than current chemical synthesis methods and 90% less than conventional plant-based extraction methods.
Willow and Noramco Inc., the world’s largest producer of high-quality synthetic cannabinoid APIs and other controlled substance APIs for the pharmaceutical and healthcare industry, have an exclusive, worldwide Joint Development Agreement (“JDA”) to design a yeast-based biosynthesis platform for the production and distribution of a highly pure CBD isolate.
The mutually exclusive agreement calls for Willow to be responsible for optimizing yeast strains in a biosynthetic process to generate ultrapure CBD at high yield and substantially lower cost compared to current methods. Noramco will leverage its decades of experience in producing and delivering CBD and pharmaceutical APIs by being responsible for the scale-up, regulatory submission, marketing and distribution of products manufactured under the JDA.
Each company will invest comparable funds, will retain the intellectual property associated with their respective scopes of work and share equally in gross profits from sales of products manufactured under the JDA.
The agreement with Noramco (http://nnw.fm/Mz1vW) addresses the increasing demand for CBD-based APIs and other CBD-infused products by pharmaceutical, nutraceutical, consumer packaged goods, beverages and other industry sectors.
The U.S. market potential of cannabinoids is significant, with industry analysts projecting $50 billion in cannabinoid-based pharmaceutical sales and $16 billion in CBD consumer goods retail sales by 2025. As of June 2019, 34 U.S. states and the District of Columbia, Guam, Puerto Rico and U.S. Virgin Islands have legalized cannabis for medical use. Another 13 states and territories have approved recreational cannabis for adult use while other states are considering similar measures.
The cannabinoid API market continues to evolve with CBD and other cannabinoid-based treatment options currently in clinical trials for indications such as post-traumatic stress syndrome, epilepsy, Parkinson’s disease, chronic pain, schizophrenia, cancer treatments and other challenging unmet medical conditions.
Willow is fully funded after raising $29 million via private placement and $8 million in exercised warrants by Tuatara Capital Fund II, L.P. Proceeds of the funding will be used to enhance the existing laboratory space in Calgary and Vancouver, Canada, and in San Francisco, California. The company anticipates exiting 2020 with $15.8 million in cash.
President and CEO Trevor Peters is an experienced executive who co-founded four startup companies in the past 15 years. He has raised over $1 billion in equity and debt financings at various stages of corporate development and has been integral to successful transactions totaling over $4 billion on sale. Mr. Peters previously was chief financial officer at Caracal Energy Inc., which sold to Glencore plc in 2014 for $1.8 billion.
Chief Financial Officer Travis Doupe has over 18 years of experience in financial leadership roles, principally in the international oil and gas industry, where he provided corporate strategic direction while overseeing all aspects of financial operations. Mr. Doupe is the treasurer and a member of the board of directors of the Canada Council for the Americas – Alberta and holds a CA-CPA designation and earned a bachelor’s degree in management from the University of Calgary.
Dr. Peter Facchini, Chief Scientific Officer, has been professor of plant biochemistry in the Department of Biological Sciences at the University of Calgary since 1995. He is recognized internationally as a leader in plant specialized metabolite biosynthesis. Dr. Facchini is the Canada Research Chair in Plant Metabolic Processes Biotechnology and has published more than 150 research papers and scholarly articles. Dr. Facchini received a PhD from the University of Toronto and conducted postdoctoral research at the University of Kentucky and Université de Montréal.
Dr. Joseph Tucker, Executive Chairman of the Board of Directors, holds more than 20 issued or pending patents and is a member of the Board of Directors of BioAlberta. He has extensive senior leadership experience in multiple public and private biotech companies. Dr. Tucker received a PhD in biochemistry and molecular biology from the University of Calgary.
Willow Biosciences Inc. (CSE: WLLW), closed Monday's trading session at $1.32, even for the day, on 4,775 volume with 12 trades. The average volume for the last 3 months is 42,394 and the stock's 52-week low/high is $1.12/$5.25.
- 420 with CNW – Michigan Caregivers Grow More than a Million Marijuana Plants
- Willow Biosciences Inc. (CSE: WLLW) Joint Development Agreement to Create Biosynthesis Platform for CBD Production, Distribution
- Synthetic Cannabinoids: The New Age of Medical Marijuana-- CFN Media
Sproutly Canada, Inc. (OTCQB: SRUTF) (CSE: SPR) (FRA: 38G)
Sproutly Canada (CSE: SPR) (OTCQB: SRUTF) (FRA: 38G) this morning announced recent cannabis production results at its wholly owned subsidiary Toronto Herbal Remedies Inc. (“THR”). According to the update, the total cultivation output of dry cannabis flower for the three-month period ended June 30, 2019, is 298kg compared to design capacity of 199kg. To view the full press release, visit: http://nnw.fm/bOEF3.
Sproutly Canada, Inc. (OTCQB: SRUTF) (TSX.V: SPR) (FRA: 38G) is developing and bringing to market cannabis consumer products with a focus on beverages. The company’s core mission is to become the leading supplier of water-soluble cannabis solutions and bio-natural oils for brands in the emerging cannabis beverage and edibles market.
To make this happen, Sproutly acquired Infusion Biosciences to bring to market a patent-pending Aqueous Phytorecovery Process (APP) technology, a fundamental paradigm shift within the cannabis industry. Replacing traditional water-compatible solutions with true natural water solubility improves the body’s ability to utilize cannabinoids, making the effect of the cannabis almost immediate.
This revolutionary process doesn’t alter the cannabis compounds and provides an onset time and offset time that mimics the same effects as inhaled marijuana. That means consumers may feel effects in five minutes or less and be free from the desired effect in approximately 90 minutes—a vastly different ingestion pattern than current methods. In addition, the water-based cannabinoids can be mixed with other liquids and stay dissolved in those liquids. The application of water-soluble cannabis infusions has potential to be widespread in both medicinal and recreational cannabis sectors, giving Sproutly a distinctive edge in a market with untapped potential.
Sproutly’s business model is focused on processing rather than cultivating, which means its success is not constrained to growing its own cannabis. The company does own a Toronto-based, ACMPR-licensed facility designed and built with a focus on cultivating pharmaceutical-grade cannabis to produce and formulate the first natural, truly water-soluble cannabis solution. Its water-soluble ingredients and bio-natural oils will deliver revolutionary brands to international markets that are searching for well-defined commercial products.
Sproutly’s entrance in the cannabis market is perfectly timed as cannabis is moving towards mainstream acceptance. Potential users are, however, interested in consuming cannabis products as drinks and using it as oils rather than smoking. The potential cannabis beverage market is staggering, and with Sproutly owning the exclusive rights to APP technology in Canada, Australia, Jamaica, Israel and the entire European Union, the company is looking at significant international expansion opportunities.
Sproutly plans to capitalize on these international opportunities by executing on partnerships with local and globally established consumer brands to leverage their existing customer bases, expand brand loyalty, and assist with marketing and support distribution networks to deliver scientific breakthroughs with speed and efficiency?worldwide.
Sproutly believes that talent drives growth. The company is committed to bringing together the best and brightest minds in the cannabis space to help with their mission to disrupt the global beverage and consumables market.
President, CEO and Director Keith Dolo recently served for more than 13 years with Robert Half, an S&P 500, NYSE-listed company. At Robert Half, Dolo held the position of vice president for more than eight years, as well as other senior roles in both operations and sales. He also sits on an advisory committee and a board position for two nonprofits in Vancouver, BC.
Chief Science Officer and Director Dr. Arup Sent has more than 35 years of experience in research and executive management at biotechnology and pharmaceutical companies. He was awarded a PhD in biochemistry from Princeton University and is a former faculty member at the National Cancer Institute and Scripps Research Institute. Sen is the inventor on five U.S. patents and numerous international patents and patent-pending applications.
Chief Financial Officer Craig Loverock is a chartered professional accountant with over 20 years of experience in accounting and finance roles in Canada, the United States and the United Kingdom. He has extensive expertise in public company reporting and transactional experience, having served as the senior financial advisor to the chairman at Magna International and acting as chief compliance officer and CFO for a private equity firm.
Head Grower Frank Han has over 12 years of experience in the horticulture industry. A previous master grower in a large commercial facility, Han has impressive expertise in all growing methods, techniques and procedures. He brings with him a wealth of knowledge in cloning, nutrient and overall plant management. Han will be in charge of the production team at Sproutly’s Toronto Herbal Remedies facility.
Sproutly Canada, Inc. (OTCQB: SRUTF), closed the day's trading session at $3.68, up 1.66%, on 17,800 volume with 55 trades. The average volume for the last 3 months is 131,500 and the stock's 52-week low/high is $3.11/$8.00.
- Sproutly Canada Inc. (CSE: SPR) (OTCQB: SRUTF) (FRA: 38G) Announces THR Subsidiary Cannabis Cultivation Results that Outperform Design Capacity by 50%
- Sproutly Announces Plans to Launch BioNatural Oil Products Under CALIBER Brand
- Sproutly Canada Inc. (CSE: SPR) (OTCQB: SRUTF) (FRA: 38G) Releases Financial Results, Announces Strategic Accomplishments for Fiscal 2019
VPR Brands, LP (VPRB)
VPR Brands, LP (VPRB), an innovative technology holding company whose assets include patented atomization-related products and technology, today announces the broadcast of its exclusive audio interview with NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community. The interview can be heard at http://nnw.fm/Y7g6h.
Florida-based VPR Brands, LP (VPRB) is an innovative technology holding company whose assets include patented atomization-related products and technology. VPR Brands' current lineup of products includes accessories and vaporizers for cannabidiol (CBD), cannabis concentrates and extracts. The company is also engaged in product development within the vaping market and partners with top international brands to elevate their products within the vaping industry.
VPR Brands employs a growth strategy centered on high-performance, high-quality products that build exponential brand equity, awareness and loyalty. The company's current product portfolio is comprised of the following:
- GoldLine combines premium ingredients and extracts coupled with the newest in technology to achieve the ultimate selection of cannabidiol (CBD) and hemp-based products available anywhere. The product range is designed for a wide variety of consumers and features edibles such as gummies and pure honey stix, tinctures, pre-rolled flower, vapable products and creams. For more information please visit?www.cbdgoldline.com.
- HoneyStick is a lifestyle brand that combines the features of high tech, high performance, dependability and affordability when it comes to upper tier vaporizers. HoneyStick was first to market in creating a Sub Ohm vaporizer to the latest Ripper and Plasma GQ. The HoneyStick team works with a vast network of growers, extractors and industry figures to bring the needs of patients and recreational users to life. HoneyStick is sold online and through a diverse network of distributors, e-tailers, dispensaries and smoke shops. For more information about HoneyStick, visit?www.vapehoneystick.com.
- Helium brings the vaping experience to a new level with intense flavors that are steeped to perfection and chilled at 20 degrees below room temperature. Helium's chillers are scientifically proven to preserve flavor, freshness and aroma. Helium is in a 50ml durable and squeezable bottle with drip tip that is functional from the start, engineered to deliver 77 percent VG.
- Vaporin delivers Sub Ohm series starter kits. Vaporin also provides an eye-catching display case with multi-packs of selected starter kits, coils and premium e-liquids for retail and dispensary operations.
- Vaporx offers the most current, highest quality products from the best-known brands, including KangerTech, eLeaf, Aspire, Pioneer4You, JoyeTech, Samsung. Vaporx acts as an extension to a client's purchasing department, providing the option to schedule regular product mix refresh for maximum sales.
- GoldLine Hemp products are developed specifically for the convenience store market segment. GoldLine Hemp-only products are created without CBD, providing an alternative product line for consumers who are not ready to experience CBD products but still want to take advantage of this rapidly expanding class of products. GoldLine Hemp-only edible Hemp Gummies debuted at the National Association of Convenience Stores (NACS) Expo in Las Vegas in October 2018 and are now being distributed nationwide. The U.S. convenience store industry, with more than 154, 000 stores nationwide, serves 160 million customers daily and has sales that are 10.8% of the total U.S. retail and food service sales. Visit?www.goldlinehemp.com?for more information about GoldLine Hemp-only products.
- Vapor Store Direct in Fort Lauderdale, Florida, is one of the largest vaporizer and e-liquid wholesalers in the United States. Vapor Store Direct stocks internationally elite brands, vaporizers, tanks/atomizers, coils, e-liquid, e-cigarettes, batteries, glass and accessories.
CEO Kevin Frija is a veteran entrepreneur with nearly 30 years of experience in sourcing, manufacturing, supply chain management, marketing, advertising and brand licensing. In 2009, Frija became the president and chief executive officer of Vapor Corp., one of the first U.S. importers and publicly traded electronic cigarette companies. In 2016, Frija purchased the brands and wholesale business assets from Vapor Corp., which is now owned by VPR Brands. Under his leadership, VPR Brands is pivoting toward cannabis products which is increasing sales and profit margins.
Dan Hoff, chief operating officer, has worked in the vaporizer and e-cigarette industry, serving in various positions at Vapor Corp., including overseeing the financial management, accounting functions, supply chain management, product design and development, and key vendor relations. He has played a pivotal role in building and expanding the cannabis-based products division at VPR Brands, which includes a turnkey OEM vapor solutions program available to farmers, cultivators and extractors. Hoff received his bachelor's degree from the University of Miami School of Business.
VPR Brands, LP (VPRB), closed the day's trading session at $6.40, up 6.14%, on 304,270 volume with 551 trades. The average volume for the last 3 months is 264,660 and the stock's 52-week low/high is $2.74/$8.42.
- VPRB Brands, LP Featured in Exclusive NetworkNewsWire Broadcast
- HoneyStick BeeBox Pro 2-in-1 - One of a kind device - Vaping will never Bee the same again!
- VPR Brands LP (VPRB) Updates Product, Increases Exposure
Spectrum Global Solutions, Inc. (SGSI)
Leading telecommunications engineering and infrastructure services provider Spectrum Global Solutions (OTCQB: SGSI) is eyeing a profitable future as the introduction of higher-speed, next-generation 5G networks approaches. To view the full article, visit: http://nnw.fm/T8odY.
Spectrum Global Solutions, Inc. (SGSI) is a leading single-source provider of end-to-end, next-generation wireless and wireline network infrastructure services and staffing solutions to the service provider (carrier) and corporate enterprise markets across the United States, Canada, Puerto Rico, Guam and the Caribbean. Spectrum Global Solutions provides services directly to carriers, aggregators, utilities, enterprise, Project Management Organizations (PMO) and Original Equipment Manufacturers (OEM) clientele through the following subsidiaries:
- AW Solutions, Inc. and AW Solutions Puerto Rico, LLC – Provides best-in-class communications infrastructure deployment services to carriers, OEMs, PMOs, utilities and enterprise clients by offering discrete and full turnkey service solutions for wireless and wireline clientele. AW Solutions holds professional engineering licenses in all contiguous states and in the District of Columbia and Hawaii; the Canadian provinces of British Columbia, Quebec, Ontario, Alberta and Newfoundland and Labrador; in Puerto Rico, Guam and the U.S. Virgin Islands.
- ADEX Corporation and ADEX Puerto Rico, LLC – An international service organization providing turnkey services and staffing solutions to telecommunications carriers and enterprise clients. Since 1993, ADEX has been assisting telecommunications companies throughout the project life cycle of any network deployment. ADEX and its service capabilities extend from the most basic installation functions to the most advanced engineering disciplines for today and tomorrow’s communications networks. Headquartered in Atlanta, Georgia, ADEX employs technical professionals and provides infrastructure services worldwide via domestic and international locations.
- Tropical Communications, Inc. – A state licensed electrical and underground utility contractor headquartered in Miami, Florida, providing all types of communications and infrastructure facility structured wiring services and solutions since 1984.
Through its subsidiaries, Spectrum Global Solutions is a comprehensive single-source provider for professional services and solutions for the development, deployment and maintenance of wireless/Distributed Antenna System (DAS)/small cell/wireline and fiber networks and infrastructure. The company’s services range in scope from a single activity to multiyear, multi-region, large-scale turnkey development contracts with a deepening pool of international, national, regional and local projects. Spectrum Global Solutions has completed more than 150,000 project activities on wireless, DAS, wireline and fiber networks across the United States utilizing licensed professional engineers, project managers, technicians and general contractors.
Growth projections for the telecom industry show a high growth cycle 2018 through 2025 with a four-fold increase in domestic mobile data traffic and up to $150 billion in fiber investment over the next 5-7 years (Deloitte, 2017). The worldwide explosion of smart phones, tablets and BYOD by customers demanding rapid deployment of new apps, private networks with better coverage and enhanced capacity provides a compelling enterprise opportunity market. The imminent rollout of 5G next generation networks, IOT (Internet-Of-Things) technology deployments, the FirstNet national public safety system, small cell/network densification, Dish Network Deployment, fiber and infrastructure network builds for backhaul and expanded deployments, new FCC spectrum auctions and upgrades to 4G, DAS and small cell networks are contributing to a projected $157 billion in U.S. telecommunication carrier capital expenditures by 2021.
CEO Roger Ponder has served as a director of Spectrum Global Solutions since April 2017. Ponder served as President/CEO of Summit Capital Advisors, LLC, and Summit Broadband, LLC a provider of consulting services to private equity and institutional banking entities in the telecommunications, cable and media/internet sectors. He also served as a member of the board of directors of InterCloud Systems, Inc. and served as its Chief Operating Officer from November 2012 to March 2015. Prior to that Ponder retired from Time Warner Kansas City Division as President/CEO. Ponder brings extensive business development, strategic planning and operational experience to the Company.
Keith Hayter is President of Spectrum Global Solutions and has served as a director of the Company since April 2017. Hayter has also served as the Chief Executive Officer and President of AW Solutions Inc. and AW Solutions Puerto Rico LLC since November 2006. He was Vice President and General Manager of Alcoa Wireless Services from 2001-2006. Hayter served in both the U.S. and British armies and brings extensive multi-national experience in the start-up, development, management and growth of companies in the telecommunication, engineering and construction industry.
Spectrum Global Solutions, Inc. (SGSI), closed the day's trading session at $0.2385, off by 14.82%, on 46,914 volume with 23 trades. The average volume for the last 3 months is 739,662 and the stock's 52-week low/high is $0.221/$2.59.
- Spectrum Global Solutions Inc. (SGSI) Ideally Positioned in High-Growth Market
- Spectrum Global Solutions Inc. (SGSI) Evolving with Acquisition of German Energy Infrastructure Tech Company
- Spectrum Global Solutions Inc. (SGSI) Positioned to Lead US 5G Network Development, Maintenance
The QualityStocks Numbers Report
QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.
The QualityStocks Sponsored News
- Cannabis Strategic Ventures, Inc. (OTCQB: NUGS) 420 with CNW – Senate Could Hold Hearings on Cannabis Banking Later this Month
- Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF) Flagship PharmHouse JV Licensed By Health Canada
- Chemistree Technology Inc. (CSE: CHM) (OTCQB: CHMJF) Completes Investment in New Jersey Cannabis Applicant - ACS
- ChineseInvestors.com (CIIX) Provides Premier Market Data Via Unique Website
- Choom Holdings Inc. (CSE: CHOO) (OTC: CHOOF) to Acquire 19.9% Equity Interest of Coastal Green, a BC-Based Cannabis Retailer
- City View Green Holdings Inc. (CSE: CVGR) Announces Debt Settlements and Other Transaction
- Consorteum Holdings, Inc. (CSRH) Universal Mobile Interface Platform Enables Communication Between Different Platforms and Devices
- Cool Events Inc. (RNWR) Reports Strong Attendance at Signature Fun Runs
- Earth Science Tech, Inc. (ETST) Stock Evaluated by InvestorPlace Analyst
- Endonovo Therapeutics (OTCQB: ENDV) SofPulse Safely Reduces Pain, Swelling
- Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX) Receives Order of QuadSight™ Prototype from Leading Japanese Tier One Supplier
- Genprex Inc. (NASDAQ: GNPX) Provides Update on Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer
- Geyser Brands Inc. (TSX.V: GYSR) Appoints Seasoned Life Sciences Executive to Board of Directors
- Golden Developing Solutions, Inc. (DVLP) Achieves Fully Reporting Status, Reports Revenue Growth
- Grapefruit Boulevard Investments Inc. (IGNG) Coverage Initiated via NetworkNewsWire
- Green Growth Brands (CSE: GGB) (OTCQB: GGBXF) Announces Bought Deal Public Offering of Units
- Green Hygienics Holdings Inc. (GRYN) Secures License for Processing Hemp in the State of North Carolina
- Hemptown USA - Acquires Leading Nutraceutical Manufacturing Facility
- INmune Bio, Inc. (NASDAQ: INMB) Innovative Drug Candidate Targets Neuroinflammation to Treat Alzheimer’s Disease
- IONIC Brands Corp. (CSE: IONC) (OTC: IONKF) Completes Acquisition of Zoots - Premium Cannabis-Infused Edibles and Infused Products
- Lexaria Bioscience Corp. (CSE: LXX)(OTC: LXRP) and Hill Street Beverage Co. Enter Global Manufacturing & Licensing Partnership
- Marijuana Company of America Inc. (MCOA) Announces Prelaunch of Premier Cannabis Delivery Service
- MustGrow Biologics Corp (CSE: MGRO) Announces R and D Program to Build on Study
- Nabis Holdings (CSE: NAB) (OTC: NABIF) (FRA: 71P) Acquires 49% Interest in Budding Cannabis Industry Disruptor
- Nightfood, Inc. (OTCQB: NGTF) Sleep-Friendly Ice Cream Featured in Oprah Magazine July Issue
- Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI) Analysts Projected Numbers Differ on Revenue Potentials but Agree on Continued Growth in CBD Products Market
- ORHub Inc. (ORHB) Settles Litigation with Former Chief Financial Officer
- Pacific Rim Cobalt Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE) President Issues Letter to Shareholders
- Pacific Software, Inc. (PFSF) Collaborates with Império for Commercial Marketing and Promotion of BOAPIN.com Trade Portal
- Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF) Achieves Key Milestone of Form 10 Registration Statement Effectiveness
- Plus Products Inc. (CSE: PLUS) (OTCQB: PLPRF) Launches Microdosing Mints, Evaluates Acquisition
- Pressure BioSciences Inc. (PBIO) Announces Second Major Contract Utilizing its BaroFold Technology Platform
- QMC Quantum Minerals Corp. (OTC: QMCQF) (TSX.V: QMC) (FSE: 3LQ) Holds Favorable Position as Rising EV Market Boosts Lithium Demand Worldwide
- Sharing Services Global Corporation (SHRG) Capitalizing on New Direct-Selling Opportunities Driven by Changing Retail Industry
- SinglePoint, Inc. (SING) Focuses on New Technologies, Offers Diverse Opportunities
- Siyata Mobile Inc. (TSX.V: SIM) (OTCQX: SYATF) Launches Uniden UV350 Desktop Dispatch Unit for Instant Communication to In-Vehicle and Mobile Enterprise Workforce
- Spectrum Global Solutions, Inc. (SGSI) Evolving with Acquisition of German Energy Infrastructure Tech Company
- Sproutly Canada, Inc. (OTC: SRUTF) (CSE: SPR) (FRA: 38G) Announces Plans to Launch BioNatural Oil Products Under CALIBER Brand
- Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTC: STLHF) Breaks Ground for Its Direct Lithium Extraction Demonstration Plant
- Sugarmade, Inc. (SGMD) 420 with CNW – Second Marijuana Home Delivery Lawsuit Filed in California
- The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) Appoints New Chief Information Officer and VP of Talent
- The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) Strong Demand for CBD Edibles to Create a $4.1 Billion Market by 2022
- Therma Bright Inc. (TSX.V: THRM) (OTC: THRBF) Continues Testing of TherOZap(TM) Technology Against the Zika Virus
- TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) 420 with CNW – Thousands Submit Comments Urging FDA to Allow CBD in Supplements and Foods
- Trxade Group Inc. (TRXD) Proprietary Web-Based TRxADE Platform Targets Nation’s Independent Pharmacy Marketplace
- VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF) 420 with CNW – Thousands Submit Comments Urging FDA to Allow CBD in Supplements and Foods
- VPR Brands, LP (VPRB) HoneyStick BeeBox Pro 2-in-1 - One of a kind device - Vaping will never Bee the same again
- Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) Doubles Retail Reach through Dillard’s Launch
- Willow Biosciences Inc. (CSE: WLLW) Joint Development Agreement to Create Biosynthesis Platform for CBD Production, Distribution
- Youngevity International, Inc. (NASDAQ: YGYI) Featured in CannabisNewsAudio Broadcast Featuring Potential Payoff in Back End of Cannabis
The QualityStocks DailyNetwork Sponsors
About The QualityStocks Daily
The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.
Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.
"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.